Phenotypes associated with this allele

• Allele Symbol: Tg(MMTV-PyVT)634Mul
• Allele Name: transgene insertion 634, William Muller
• Allele ID: MGI:2679595
• Summary: 79 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Ccn6^tm1.1Cgkl/Ccn6^tm1.1Cgkl Tg(MMTV-cre)1Mam/0 Tg(MMTV-PyVT)634Mul/0	FVB/N-Ccn6^tm1.1Cgkl Tg(MMTV-cre)1Mam Tg(MMTV-PyVT)634Mul	MGI:6093471
cn2	Ets2^tm1Rgo/Ets2^tm5.1Rgo Tg(MMTV-PyVT)634Mul/0 Tg(S100a4-cre)1Gle/0	involves: 129S2/SvPas * FVB/N	MGI:4366767
cn3	Itgb1^tm1Mll/Itgb1^tm1Mll Tg(MMTV-cre)7Mul/0 Tg(MMTV-PyVT)634Mul/0	involves: 129X1/SvJ * FVB/N	MGI:3704008
cn4	Ddr2^tm1c(EUCOMM)Wtsi/Ddr2^tm1c(EUCOMM)Wtsi Tg(KRT14-cre)1Amc/0 Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6 * C57BL/6N * CBA * FVB/N	MGI:5825268
cn5	Pdcd1^tm1.1Liux/Pdcd1^tm1.1Liux Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6 * FVB/N	MGI:5449727
cn6	Amotl1^tm1Laho/Amotl1^tm1Laho Tg(Cdh5-cre/ERT2)1Rha/0 Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6 * FVB/N	MGI:6723730
cn7	Zmynd8^em1Lwb/Zmynd8^em1Lwb Tg(MMTV-PyVT)634Mul/0 Tg(KRT14-cre)1Amc/0	involves: C57BL/6N * CBA * FVB	MGI:7432306
cn8	Zmynd8^em1Lwb/Zmynd8^em1Lwb Tg(MMTV-cre)4Mam/0 Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6N * FVB	MGI:7432304
cn9	Ddr2^tm1c(EUCOMM)Wtsi/Ddr2^tm1c(EUCOMM)Wtsi Tg(MMTV-cre)#Mam/0 Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6N * FVB * FVB/N	MGI:5825266
cx10	Adipoq^tm1Chan/Adipoq^+ Tg(MMTV-PyVT)634Mul/0	B6.Cg-Adipoq^tm1Chan Tg(MMTV-PyVT)634Mul	MGI:3841378
cx11	Cd44^tm1Mak/Cd44^tm1Mak Tg(MMTV-PyVT)634Mul/0	B6.Cg-Cd44^tm1Mak Tg(MMTV-PyVT)634Mul	MGI:4943926
cx12	F2rl1^tm1Bpd/F2rl1^tm1Bpd Tg(MMTV-PyVT)634Mul/0	B6.Cg-F2rl1^tm1Bpd Tg(MMTV-PyVT)634Mul	MGI:4821160
cx13	F2r^tm1Pago/F2r^tm1Pago Tg(MMTV-PyVT)634Mul/0	B6.Cg-F2r^tm1Pago Tg(MMTV-PyVT)634Mul	MGI:4821159
cx14	Frmd3^em1Zhaj/Frmd3^em1Zhaj Tg(MMTV-PyVT)634Mul/0	B6.Cg-Frmd3^em1Zhaj Tg(MMTV-PyVT)634Mul	MGI:7834434
cx15	Nmral1^Gt(S8-10A1)Sor/Nmral1^Gt(S8-10A1)Sor Tg(MMTV-PyVT)634Mul/0	B6.Cg-Nmral1^Gt(S8-10A1)Sor Tg(MMTV-PyVT)634Mul	MGI:6473979
cx16	Nos2^tm1Lau/Nos2^tm1Lau Tg(MMTV-PyVT)634Mul/0	B6.Cg-Nos2^tm1Lau Tg(MMTV-PyVT)634Mul	MGI:3767793
cx17	Adipoq^tm1Chan/Adipoq^tm1Chan Tg(MMTV-PyVT)634Mul/0	either: B6.Cg-Adipoq^tm1Chan Tg(MMTV-PyVT)634Mul or FVB.Cg-Adipoq^tm1Chan Tg(MMTV-PyVT)634Mul	MGI:3841377
cx18	Ctsb^tm1Jde/Ctsb^tm1Jde Tg(MMTV-PyVT)634Mul/0	FVB.129P2-Ctsb^tm1Jde Tg(MMTV-PyVT)634Mul	MGI:4436881
cx19	Ctsb^tm1Jde/Ctsb^tm1Jde Ctsz^tm1Thre/Ctsz^tm1Thre Tg(MMTV-PyVT)634Mul/0	FVB.129P2-Ctsz^tm1Thre Ctsb^tm1Jde Tg(MMTV-PyVT)634Mul	MGI:4436884
cx20	Ctsz^tm1Thre/Ctsz^tm1Thre Tg(MMTV-PyVT)634Mul/0	FVB.129P2-Ctsz^tm1Thre Tg(MMTV-PyVT)634Mul	MGI:4436882
cx21	Adipoq^tm1Chan/Adipoq^+ Tg(MMTV-PyVT)634Mul/0	FVB.Cg-Adipoq^tm1Chan Tg(MMTV-PyVT)634Mul	MGI:3841380
cx22	Mtdh^Gt(XB780)Byg/Mtdh^Gt(XB780)Byg Tg(MMTV-PyVT)634Mul/0	FVB.Cg-Mtdh^Gt(XB780)Byg Tg(MMTV-PyVT)634Mul	MGI:5649039
cx23	Mtdh^Gt(XB780)Byg/Mtdh^+ Tg(MMTV-PyVT)634Mul/0	FVB.Cg-Mtdh^Gt(XB780)Byg Tg(MMTV-PyVT)634Mul	MGI:5649043
cx24	Nos2^tm1Lau/Nos2^tm1Lau Tg(MMTV-PyVT)634Mul/0	FVB.Cg-Nos2^tm1Lau Tg(MMTV-PyVT)634Mul	MGI:3767794
cx25	Akt1^Gt1Pnt/Akt1^Gt1Pnt Tg(MMTV-PyVT)634Mul/0	involves: 129 * C57BL/6 * FVB/N	MGI:3804013
cx26	Akt3^tm1Mbb/Akt3^tm1Mbb Tg(MMTV-PyVT)634Mul/0	involves: 129 * C57BL/6 * FVB/N	MGI:3804008
cx27	Akt2^tm1.1Mbb/Akt2^tm1.1Mbb Tg(MMTV-PyVT)634Mul/0	involves: 129 * C57BL/6 * FVB/N	MGI:3804011
cx28	Cdcp1^tm1.2Moas/Cdcp1^tm1.2Moas Tg(MMTV-PyVT)634Mul/0	involves: 129 * C57BL/6 * FVB/N * SJL	MGI:5478601
cx29	Cdcp1^tm1.2Moas/Cdcp1^+ Tg(MMTV-PyVT)634Mul/0	involves: 129 * C57BL/6 * FVB/N * SJL	MGI:5478603
cx30	Plg^tm1Jld/Plg^tm1Jld Tg(MMTV-PyVT)634Mul/0	involves: 129P2/OlaHsd * Black Swiss * FVB/N	MGI:3690443
cx31	Cd44^tm1Mak/Cd44^tm1Mak Tg(MMTV-PyVT)634Mul/0	involves: 129P2/OlaHsd * C57BL/6 * FVB/N	MGI:4943925
cx32	Flot2^tm1Mak/Flot2^tm1Mak Tg(MMTV-PyVT)634Mul/0	involves: 129P2/OlaHsd * C57BL/6 * FVB/N	MGI:5527556
cx33	Fgfr4^tm1Axul/Fgfr4^tm1Axul Tg(MMTV-PyVT)634Mul/0	involves: 129P2/OlaHsd * C57BL/6 * FVB/N	MGI:4429454
cx34	Ptk2^tm3.1Guan/Ptk2^tm3.1Guan Tg(MMTV-PyVT)634Mul/0	involves: 129P2/OlaHsd * C57BL/6J * FVB/N	MGI:5485071
cx35	Kars1^Gt(AJ0130)Wtsi/Kars1^+ Tg(MMTV-PyVT)634Mul/0	involves: 129P2/OlaHsd * FVB/N	MGI:6472861
cx36	Rhoc^tm1Mak/Rhoc^tm1Mak Tg(MMTV-PyVT)634Mul/0	involves: 129P2/OlaHsd * FVB/N	MGI:3613521
cx37	Mmp7^tm1Lmm/Mmp7^tm1Lmm Tg(MMTV-PyVT)634Mul/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N	MGI:4367709
cx38	Fes^tm1Pag/Fes^tm1Pag Tg(MMTV-PyVT)634Mul/0	involves: 129S1/Sv * 129X1/SvJ * CD-1	MGI:3581867
cx39	Fes^tm2Pag/Fes^tm2Pag Tg(MMTV-PyVT)634Mul/0	involves: 129S1/Sv * 129X1/SvJ * CD-1	MGI:3581866
cx40	Shc1^tm5Paw/Shc1^+ Tg(MMTV-PyVT)634Mul/0	involves: 129S1/Sv * 129X1/SvJ * FVB/N	MGI:4361928
cx41	Grb2^tm1Paw/Grb2^+ Tg(MMTV-PyVT)634Mul/?	involves: 129S1/Sv * 129X1/SvJ * FVB/N	MGI:2679599
cx42	Shc1^tm7Paw/Shc1^+ Tg(MMTV-PyVT)634Mul/0	involves: 129S1/Sv * 129X1/SvJ * FVB/N	MGI:4361926
cx43	Shc1^tm6Paw/Shc1^+ Tg(MMTV-PyVT)634Mul/0	involves: 129S1/Sv * 129X1/SvJ * FVB/N	MGI:4361927
cx44	Shc1^tm5Paw/Shc1^tm5Paw Tg(MMTV-PyVT)634Mul/0	involves: 129S1/Sv * 129X1/SvJ * FVB/N	MGI:4361929
cx45	Shc1^tm6Paw/Shc1^tm6Paw Tg(MMTV-PyVT)634Mul/0	involves: 129S1/Sv * 129X1/SvJ * FVB/N	MGI:4361930
cx46	Ets2^tm1Rgo/Ets2^+ Tg(MMTV-PyVT)634Mul/0	involves: 129S2/SvPas * Black Swiss * FVB/N	MGI:2680919
cx47	Mmp9^tm1Tvu/Mmp9^tm1Tvu Tg(MMTV-PyVT)634Mul/0	involves: 129S6/SvEvTac * C57BL/6 * FVB/N	MGI:4367707
cx48	Mmp9^tm1Tvu/Mmp9^tm1Tvu Tg(MMTV-PyVT)634Mul/0	involves: 129S6/SvEvTac * FVB/N	MGI:4367708
cx49	Tgfb1i1^tm1.2Cet/Tgfb1i1^tm1.2Cet Tg(MMTV-PyVT)634Mul/0	involves: 129S/SvEv * C57BL/6 * FVB/N	MGI:6093700
cx50	Map3k1^tm1Glj/Map3k1^tm1Glj Tg(MMTV-PyVT)634Mul/0	involves: 129S/SvEv * FVB/N	MGI:4352683
cx51	Cav1^tm1Mls/Cav1^+ Tg(MMTV-PyVT)634Mul/0	involves: 129/Sv * C57BL/6J * FVB/N * SJL	MGI:4417966
cx52	Cav1^tm1Mls/Cav1^tm1Mls Tg(MMTV-PyVT)634Mul/0	involves: 129/Sv * C57BL/6J * FVB/N * SJL	MGI:4417965
cx53	Atf3^tm1Dron/Atf3^tm1Dron Tg(MMTV-PyVT)634Mul/0	involves: 129X1/SvJ * C57BL/6 * FVB/N	MGI:5547962
cx54	Inpp5j^tm1.1Cmit/Inpp5j^tm1.1Cmit Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6	MGI:5827714
cx55	Ube2o^tm1.1(KOMP)Mbp/Ube2o^+ Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6 * C57BL/6N * FVB/N	MGI:5902964
cx56	Ube2o^tm1.1(KOMP)Mbp/Ube2o^tm1.1(KOMP)Mbp Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6 * C57BL/6N * FVB/N	MGI:5902963
cx57	Rhoj^tm1.2Auem/Rhoj^tm1.2Auem Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6 * CBA/JNCrlj * FVB/N	MGI:5608671
cx58	Cdh13^tm1Brns/Cdh13^tm1Brns Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6 * FVB/N	MGI:3809817
cx59	Ksr1^tm1Shaw/Ksr1^tm1Shaw Tg(MMTV-PyVT)634Mul/?	involves: C57BL/6 * FVB/N	MGI:3841457
cx60	Myct1^em1Choi/Myct1^em1Choi Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6 * FVB/N	MGI:6696447
cx61	Ak6^tm1.1Zhexf/Ak6^+ Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6 * FVB/N	MGI:7859290
cx62	Mir31^em1Nju/Mir31^em1Nju Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6J * FVB/N	MGI:6358371
cx63	Ddr2^tm1a(EUCOMM)Wtsi/Ddr2^tm1a(EUCOMM)Wtsi Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6N * FVB/N	MGI:5825262
cx64	Ddr2^tm1b(EUCOMM)Wtsi/Ddr2^tm1b(EUCOMM)Wtsi Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6N * FVB/N	MGI:5825263
cx65	Trim11^em1Bcgen/Trim11^+ Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6N * FVB/N	MGI:7354957
cx66	Ccdc25^em1Smoc/Ccdc25^em1Smoc Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6NTac * FVB/N	MGI:6460271
cx67	Anxa1^tm1Rjf/Anxa1^tm1Rjf Tg(MMTV-PyVT)634Mul/?	involves: FVB/N	MGI:5431552
cx68	Mtes1^NZB/BlNJ/Mtes1^NZB/BlNJ Tg(MMTV-PyVT)634Mul/0	involves: FVB/NJ * FVB/N-Tg(MMTV-PyVT)634Mul/J * I/LnJ	MGI:3579341
cx69	Mmtp3^NZB/BlNJ/Mmtp3^NZB/BlNJ Tg(MMTV-PyVT)634Mul/0	involves: FVB/NJ * FVB/N-Tg(MMTV-PyVT)634Mul/J * I/LnJ	MGI:3579340
cx70	Mmtp2^NZB/BlNJ/Mmtp2^NZB/BlNJ Tg(MMTV-PyVT)634Mul/0	involves: FVB/NJ * FVB/N-Tg(MMTV-PyVT)634Mul/J * I/LnJ	MGI:3579339
cx71	Mmtp1^I/LnJ/Mmtp1^I/LnJ Tg(MMTV-PyVT)634Mul/0	involves: FVB/NJ * FVB/N-Tg(MMTV-PyVT)634Mul/J * I/LnJ	MGI:3579338
cx72	Slc6a14^tm1Gana/Slc6a14^tm1Gana Tg(MMTV-PyVT)634Mul/0	Not Specified	MGI:5807361
tg73	Tg(MMTV-PyVT)634Mul/0	B6.FVB-Tg(MMTV-PyVT)634Mul	MGI:7834440
tg74	Tg(MMTV-PyVT)634Mul/0	FVB/N-Tg(MMTV-PyVT)634Mul/J	MGI:3841379
tg75	Tg(MMTV-PyVT)634Mul/0	FVB/N-Tg(MMTV-PyVT)634Mul/Nci	MGI:2679598
tg76	Tg(MMTV-PyVT)634Mul/0	involves: 129 * C57BL/6 * FVB/N	MGI:3804002
tg77	Tg(MMTV-PyVT)634Mul/0	involves: C57BL/6 * FVB/N	MGI:3841381
tg78	Tg(MMTV-PyVT)634Mul/0	involves: FVB/N	MGI:4361924
tg79	Tg(MMTV-PyVT)634Mul/0	multiple strains	MGI:3032640

Genotype
MGI:6093471

cn1

• Allelic Composition: Ccn6^tm1.1Cgkl/Ccn6^tm1.1Cgkl; Tg(MMTV-cre)1Mam/0; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: FVB/N-Ccn6^tm1.1Cgkl Tg(MMTV-cre)1Mam Tg(MMTV-PyVT)634Mul

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:241259 )

♀ • mice develop mammary tumors with no differences in primary tumor volume from control mice expressing Tg(MMTV-PyVT)654Mul and Tg(MMTV-cre)1Mam

integument

increased mammary adenocarcinoma incidence ( J:241259 )

♀ • mice develop mammary tumors with no differences in primary tumor volume from control mice expressing Tg(MMTV-PyVT)654Mul and Tg(MMTV-cre)1Mam

neoplasm

increased mammary adenocarcinoma incidence ( J:241259 )

♀ • mice develop mammary tumors with no differences in primary tumor volume from control mice expressing Tg(MMTV-PyVT)654Mul and Tg(MMTV-cre)1Mam

increased metastatic potential ( J:241259 )

♀ • female virgin mice show an increase in the number of lung metastasis compared to control mice expressing Tg(MMTV-PyVT)654Mul and Tg(MMTV-cre)1Mam

Genotype
MGI:4366767

cn2

• Allelic Composition: Ets2^tm1Rgo/Ets2^tm5.1Rgo; Tg(MMTV-PyVT)634Mul/0; Tg(S100a4-cre)1Gle/0
• Genetic Background: involves: 129S2/SvPas * FVB/N

neoplasm

decreased mammary gland tumor incidence ( J:153747 )

• fewer mammary tumors form than in Ets2^tm1Rgo/Ets2^tm5.1Rgo Tg(MMTV-PyVT)634Mul mice and progression to adenoma and early carcinoma is slowed

integument

decreased mammary gland tumor incidence ( J:153747 )

• fewer mammary tumors form than in Ets2^tm1Rgo/Ets2^tm5.1Rgo Tg(MMTV-PyVT)634Mul mice and progression to adenoma and early carcinoma is slowed

endocrine/exocrine glands

decreased mammary gland tumor incidence ( J:153747 )

• fewer mammary tumors form than in Ets2^tm1Rgo/Ets2^tm5.1Rgo Tg(MMTV-PyVT)634Mul mice and progression to adenoma and early carcinoma is slowed

Genotype
MGI:3704008

cn3

• Allelic Composition: Itgb1^tm1Mll/Itgb1^tm1Mll; Tg(MMTV-cre)7Mul/0; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129X1/SvJ * FVB/N

neoplasm

decreased mammary gland tumor incidence ( J:92547 )

• mammary tumors are not detected at 10 weeks of age, like they are in control mice expressing Tg(MMTV-PyVT)634Mul

• although palpable mammary tumors are detected after 4 months of age, these tumors are composed of cells which fail to express the cre transgene and thus express Itgb1

integument

decreased mammary gland tumor incidence ( J:92547 )

• mammary tumors are not detected at 10 weeks of age, like they are in control mice expressing Tg(MMTV-PyVT)634Mul

• although palpable mammary tumors are detected after 4 months of age, these tumors are composed of cells which fail to express the cre transgene and thus express Itgb1

endocrine/exocrine glands

decreased mammary gland tumor incidence ( J:92547 )

• mammary tumors are not detected at 10 weeks of age, like they are in control mice expressing Tg(MMTV-PyVT)634Mul

• although palpable mammary tumors are detected after 4 months of age, these tumors are composed of cells which fail to express the cre transgene and thus express Itgb1

Genotype
MGI:5825268

cn4

• Allelic Composition: Ddr2^{tm1c(EUCOMM)Wtsi}/Ddr2^{tm1c(EUCOMM)Wtsi}; Tg(KRT14-cre)1Amc/0; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6 * C57BL/6N * CBA * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:236031 )

• mice show a similar primary mammary gland tumor growth and tumor burden as single Tg(MMTV-PyVT)634Mul/0 mice and similar levels of fibrillar collagen in tumors

decreased metastatic potential ( J:236031 )

• mice show a reduction in the number of lung metastasis compared to single Tg(MMTV-PyVT)634Mul/0 mice

• in collagen I gels, a reduction in the number of invasive tumor organoids is seen

• however, in matrigel, tumor organoids show similar organoid budding and branching as single Tg(MMTV-PyVT)634Mul tumor organoids

integument

increased mammary gland tumor incidence ( J:236031 )

• mice show a similar primary mammary gland tumor growth and tumor burden as single Tg(MMTV-PyVT)634Mul/0 mice and similar levels of fibrillar collagen in tumors

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:236031 )

• mice show a similar primary mammary gland tumor growth and tumor burden as single Tg(MMTV-PyVT)634Mul/0 mice and similar levels of fibrillar collagen in tumors

Genotype
MGI:5449727

cn5

• Allelic Composition: Pdcd1^tm1.1Liux/Pdcd1^tm1.1Liux; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6 * FVB/N

Reduced tumor growth in Pdcd1^tm1.1Liux/Pdcd1^tm1.1Liux Tg(MMTV-PyVT)634Mul/0 mice

mortality/aging

extended life span ( J:190150 )

• mice survive longer than Pdcd1⁺/Pdcd1^tm1.1Liux Tg(MMTV-PyVT)634Mul mice

neoplasm

decreased tumor growth/size ( J:190150 )

• reduced tumor growth compared to in Pdcd1⁺/Pdcd1^tm1.1Liux Tg(MMTV-PyVT)634Mul mice

increased tumor latency ( J:190150 )

• compared with Pdcd1⁺/Pdcd1^tm1.1Liux Tg(MMTV-PyVT)634Mul mice

immune system

increased T-helper 1 cell number ( J:190150 )

• in tumors 0447. smb 1/21/13

decreased T-helper 17 cell number ( J:190150 )

• in tumors

decreased T-helper 2 cell number ( J:190150 )

• in tumors

decreased regulatory T cell number ( J:190150 )

• in tumors

increased interferon-gamma secretion ( J:190150 )

• in tumor-infiltrating CD4+ and CD8+ T cells

decreased interleukin-17 secretion ( J:190150 )

• of Il17a in tumor-infiltrating CD4+ T cells

increased interleukin-2 secretion ( J:190150 )

• in tumor-infiltrating CD4+ and CD8+ T cells

increased tumor necrosis factor secretion ( J:190150 )

• in tumor-infiltrating CD4+ and CD8+ T cells

cellular

increased apoptosis ( J:190150 )

• of tumor cells compared to in Pdcd1⁺/Pdcd1^tm1.1Liux Tg(MMTV-PyVT)634Mul mice

hematopoietic system

increased T-helper 1 cell number ( J:190150 )

• in tumors 0447. smb 1/21/13

decreased T-helper 17 cell number ( J:190150 )

• in tumors

decreased T-helper 2 cell number ( J:190150 )

• in tumors

decreased regulatory T cell number ( J:190150 )

• in tumors

Genotype
MGI:6723730

cn6

• Allelic Composition: Amotl1^tm1Laho/Amotl1^tm1Laho; Tg(Cdh5-cre/ERT2)1Rha/0; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6 * FVB/N

cardiovascular system

abnormal tumor vascularization ( J:253854 )

• mice injected with tamoxifen show significantly enlarged and dilated infiltrating blood vessels in the mammary tumor area relative to control mice, as determined by vessel diameter

• however, adult retinal vessels from these mice exhibit no changes in vessel diameter

neoplasm

abnormal tumor vascularization ( J:253854 )

• mice injected with tamoxifen show significantly enlarged and dilated infiltrating blood vessels in the mammary tumor area relative to control mice, as determined by vessel diameter

• however, adult retinal vessels from these mice exhibit no changes in vessel diameter

increased tumor latency ( J:253854 )

• mice injected with tamoxifen exhibit a longer lag time until mammary gland tumors are detected relative to control mice

• however, overall tumor progression is not affected

Genotype
MGI:7432306

cn7

• Allelic Composition: Zmynd8^em1Lwb/Zmynd8^em1Lwb; Tg(MMTV-PyVT)634Mul/0; Tg(KRT14-cre)1Amc/0
• Genetic Background: involves: C57BL/6N * CBA * FVB

endocrine/exocrine glands

decreased mammary gland tumor incidence ( J:326848 )

• strongly reduced mammary tumor number and weight with no metastasis to the lungs unlike in control mice

integument

decreased mammary gland tumor incidence ( J:326848 )

• strongly reduced mammary tumor number and weight with no metastasis to the lungs unlike in control mice

neoplasm

decreased mammary gland tumor incidence ( J:326848 )

• strongly reduced mammary tumor number and weight with no metastasis to the lungs unlike in control mice

Genotype
MGI:7432304

cn8

• Allelic Composition: Zmynd8^em1Lwb/Zmynd8^em1Lwb; Tg(MMTV-cre)4Mam/0; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6N * FVB

neoplasm

decreased mammary gland tumor incidence ( J:326848 )

• reduced mammary tumor number and weight with no metastasis to the lungs unlike in control mice

integument

decreased mammary gland tumor incidence ( J:326848 )

• reduced mammary tumor number and weight with no metastasis to the lungs unlike in control mice

endocrine/exocrine glands

decreased mammary gland tumor incidence ( J:326848 )

• reduced mammary tumor number and weight with no metastasis to the lungs unlike in control mice

Genotype
MGI:5825266

cn9

• Allelic Composition: Ddr2^{tm1c(EUCOMM)Wtsi}/Ddr2^{tm1c(EUCOMM)Wtsi}; Tg(MMTV-cre)#Mam/0; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6N * FVB * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:236031 )

• mice show a similar primary mammary gland tumor growth and tumor burden as single Tg(MMTV-PyVT)634Mul/0 mice, no differences in the number of lung metastases, and similar levels of fibrillar collagen in tumors

integument

increased mammary gland tumor incidence ( J:236031 )

• mice show a similar primary mammary gland tumor growth and tumor burden as single Tg(MMTV-PyVT)634Mul/0 mice, no differences in the number of lung metastases, and similar levels of fibrillar collagen in tumors

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:236031 )

• mice show a similar primary mammary gland tumor growth and tumor burden as single Tg(MMTV-PyVT)634Mul/0 mice, no differences in the number of lung metastases, and similar levels of fibrillar collagen in tumors

Genotype
MGI:3841378

cx10

• Allelic Composition: Adipoq^tm1Chan/Adipoq⁺; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: B6.Cg-Adipoq^tm1Chan Tg(MMTV-PyVT)634Mul

Increased metastatic capacity of tumor cells from Adipoq^tm1Chan/Adipoq⁺ Tg(MMTV-PyVT)634Mul/0 mice

neoplasm

increased mammary gland tumor incidence ( J:147458 )

• mice develop mammary gland tumors with a median age of tumor latency of 66 days in females and 114 days in males compared to 73 days and 137 days in female and male Tg(MMTV-PyVT)634Mul mice, respectively

• mice develop tumors with a basal-like subtype

increased metastatic potential ( J:147458 )

• tumor cells implanted into nude mice exhibit increased proliferation and are more aggressive than tumor cells isolated from Tg(MMTV-PyVT)634Mul mice

• tumor cells from male mice exhibit increased metastatic capacity in nude mice compared to tumor cells from Tg(MMTV-PyVT)634Mul mice

abnormal tumor morphology ( J:147458 )

• proliferation of tumor-derived cells is more sensitive to adiponectin-mediated inhibition of cell proliferation than tumor cells from Tg(MMTV-PyVT)634Mul mice

increased tumor growth/size ( J:147458 )

• total wet weight of tumors is 2-fold heavier than in Tg(MMTV-PyVT)634Mul mice

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:147458 )

• mice develop mammary gland tumors with a median age of tumor latency of 66 days in females and 114 days in males compared to 73 days and 137 days in female and male Tg(MMTV-PyVT)634Mul mice, respectively

• mice develop tumors with a basal-like subtype

respiratory system

increased lung weight ( J:147458 )

integument

increased mammary gland tumor incidence ( J:147458 )

• mice develop mammary gland tumors with a median age of tumor latency of 66 days in females and 114 days in males compared to 73 days and 137 days in female and male Tg(MMTV-PyVT)634Mul mice, respectively

• mice develop tumors with a basal-like subtype

homeostasis/metabolism

decreased circulating adiponectin level ( J:147458 )

• 4- to 5-fold

growth/size/body

increased lung weight ( J:147458 )

Genotype
MGI:4943926

cx11

• Allelic Composition: Cd44^tm1Mak/Cd44^tm1Mak; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: B6.Cg-Cd44^tm1Mak Tg(MMTV-PyVT)634Mul

neoplasm

increased metastatic potential ( J:100774 )

• an increase in the percentage of mice developing metastases at 14 weeks, compared with Cd44^tm1Mak/+, Tg(MMTV-PyVT)634Mul mice

• a greater number of metastases per lung

Genotype
MGI:4821160

cx12

• Allelic Composition: F2rl1^tm1Bpd/F2rl1^tm1Bpd; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: B6.Cg-F2rl1^tm1Bpd Tg(MMTV-PyVT)634Mul

cardiovascular system

abnormal tumor vascularization ( J:138924 )

• mutants show a delayed angiogenic switch in breast tumors, with decreased vessel infiltration in and around tumors compared to Tg(MMTV-PyVT)634Mul mice

neoplasm

abnormal tumor vascularization ( J:138924 )

• mutants show a delayed angiogenic switch in breast tumors, with decreased vessel infiltration in and around tumors compared to Tg(MMTV-PyVT)634Mul mice

decreased mammary gland tumor incidence ( J:138924 )

• adenomas and mammary adenocarcinoma develop slower in mutants than in Tg(MMTV-PyVT)634Mul mice resulting in reduced metastasis

increased mammary adenocarcinoma incidence ( J:138924 )

• delay in the appearance of palpable tumors and progression of mammary adenocarcinoma compared Tg(MMTV-PyVT)634Mul mice

increased adenoma incidence ( J:138924 )

• adenomas develop at a slower rate in mutants than in Tg(MMTV-PyVT)634Mul mice

endocrine/exocrine glands

decreased mammary gland tumor incidence ( J:138924 )

• adenomas and mammary adenocarcinoma develop slower in mutants than in Tg(MMTV-PyVT)634Mul mice resulting in reduced metastasis

increased mammary adenocarcinoma incidence ( J:138924 )

• delay in the appearance of palpable tumors and progression of mammary adenocarcinoma compared Tg(MMTV-PyVT)634Mul mice

integument

decreased mammary gland tumor incidence ( J:138924 )

• adenomas and mammary adenocarcinoma develop slower in mutants than in Tg(MMTV-PyVT)634Mul mice resulting in reduced metastasis

increased mammary adenocarcinoma incidence ( J:138924 )

• delay in the appearance of palpable tumors and progression of mammary adenocarcinoma compared Tg(MMTV-PyVT)634Mul mice

Genotype
MGI:4821159

cx13

• Allelic Composition: F2r^tm1Pago/F2r^tm1Pago; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: B6.Cg-F2r^tm1Pago Tg(MMTV-PyVT)634Mul

neoplasm

increased mammary adenocarcinoma incidence ( J:138924 )

• progression of mammary adenocarcinoma development occurs to a similar extent as in Tg(MMTV-PyVT)634Mul mice

increased adenoma incidence ( J:138924 )

• adenomas develop by 9 weeks of age, at similar time and rate as in Tg(MMTV-PyVT)634Mul mice

integument

increased mammary adenocarcinoma incidence ( J:138924 )

• progression of mammary adenocarcinoma development occurs to a similar extent as in Tg(MMTV-PyVT)634Mul mice

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:138924 )

• progression of mammary adenocarcinoma development occurs to a similar extent as in Tg(MMTV-PyVT)634Mul mice

Genotype
MGI:7834434

cx14

• Allelic Composition: Frmd3^em1Zhaj/Frmd3^em1Zhaj; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: B6.Cg-Frmd3^em1Zhaj Tg(MMTV-PyVT)634Mul

neoplasm

increased mammary gland tumor incidence ( J:350496 )

• mice show larger volume and increased number of tumors at 120 days of age than in single Tg(MMTV-PyVT)634Mul/0 mice

• tumors show syncytial growth, a pushing border, and areas of necrosis with increased proliferation at the invasive edge

• following orthotopic transplantation into wild-type recipient mice, mutant cells show a higher tumor incidence, and have a larger volume and higher proliferation, indicating increased stemness of cancer

increased mammary adenocarcinoma incidence ( J:350496 )

• in late stage carcinoma, tumors are estrogen receptor-negative and progesterone receptor negative (ER-PR-)

• tumors show up-regulation of CK5 and down-regulation of CK8, indicating expansion of basal cells and inhibition of luminal cell differentiation

increased tumor growth/size ( J:350496 )

• mammary glands exhibit fewer but larger tumors at week 9 (preneoplastic stage) than in single Tg(MMTV-PyVT)634Mul/0 mice

• primary tumor cells form more and larger mammospheres at day 5 of culture than tumor cells from single Tg(MMTV-PyVT)634Mul/0 mice

decreased tumor latency ( J:350496 )

• mice show accelerated mammary gland tumor progression compared to single Tg(MMTV-PyVT)634Mul/0 mice

• however, overall tumor-free survival duration is similar to single Tg(MMTV-PyVT)634Mul/0 mice

endocrine/exocrine glands

increased mammary gland epithelial cell proliferation ( J:350496 )

• increase in the number of proliferating cells in mammary glands at weeks 6 and 8 compared to single Tg(MMTV-PyVT)634Mul/0 mice

increased mammary gland tumor incidence ( J:350496 )

• mice show larger volume and increased number of tumors at 120 days of age than in single Tg(MMTV-PyVT)634Mul/0 mice

• tumors show syncytial growth, a pushing border, and areas of necrosis with increased proliferation at the invasive edge

• following orthotopic transplantation into wild-type recipient mice, mutant cells show a higher tumor incidence, and have a larger volume and higher proliferation, indicating increased stemness of cancer

increased mammary adenocarcinoma incidence ( J:350496 )

• in late stage carcinoma, tumors are estrogen receptor-negative and progesterone receptor negative (ER-PR-)

• tumors show up-regulation of CK5 and down-regulation of CK8, indicating expansion of basal cells and inhibition of luminal cell differentiation

increased mammary gland apoptosis ( J:350496 )

• enhanced apoptosis is seen in mammary glands at weeks 6 and 8 compared to single Tg(MMTV-PyVT)634Mul/0 mice

integument

increased mammary gland epithelial cell proliferation ( J:350496 )

• increase in the number of proliferating cells in mammary glands at weeks 6 and 8 compared to single Tg(MMTV-PyVT)634Mul/0 mice

increased mammary gland tumor incidence ( J:350496 )

• mice show larger volume and increased number of tumors at 120 days of age than in single Tg(MMTV-PyVT)634Mul/0 mice

• tumors show syncytial growth, a pushing border, and areas of necrosis with increased proliferation at the invasive edge

• following orthotopic transplantation into wild-type recipient mice, mutant cells show a higher tumor incidence, and have a larger volume and higher proliferation, indicating increased stemness of cancer

increased mammary adenocarcinoma incidence ( J:350496 )

• in late stage carcinoma, tumors are estrogen receptor-negative and progesterone receptor negative (ER-PR-)

• tumors show up-regulation of CK5 and down-regulation of CK8, indicating expansion of basal cells and inhibition of luminal cell differentiation

increased mammary gland apoptosis ( J:350496 )

• enhanced apoptosis is seen in mammary glands at weeks 6 and 8 compared to single Tg(MMTV-PyVT)634Mul/0 mice

cellular

increased mammary gland epithelial cell proliferation ( J:350496 )

• increase in the number of proliferating cells in mammary glands at weeks 6 and 8 compared to single Tg(MMTV-PyVT)634Mul/0 mice

Genotype
MGI:6473979

cx15

• Allelic Composition: Nmral1^{Gt(S8-10A1)Sor}/Nmral1^{Gt(S8-10A1)Sor}; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: B6.Cg-Nmral1^{Gt(S8-10A1)Sor} Tg(MMTV-PyVT)634Mul

neoplasm

decreased mammary gland tumor incidence ( J:282813 )

• at 150 days of age, mammary adenocarcinoma number is significantly lower than that in Tg(MMTV-PyVT)634Mul/0 mice and Nmral1^{Gt(S8-10A1)Sor}/Nmral1⁺ Tg(MMTV-PyVT)634Mul/0 mice

decreased tumor growth/size ( J:282813 )

• at 150 days of age, total mammary tumor weight is significantly lower than that in Tg(MMTV-PyVT)634Mul/0 mice and Nmral1^{Gt(S8-10A1)Sor}/Nmral1⁺ Tg(MMTV-PyVT)634Mul/0 mice

increased tumor latency ( J:282813 )

• mice show a significant delay in the development of mammary tumors with only about half (7/12) of mice developing tumors by 150 days of age, whereas all but one (17/18) of Tg(MMTV-PyVT)634Mul/0 mice and Nmral1^{Gt(S8-10A1)Sor}/Nmral1⁺ Tg(MMTV-PyVT)634Mul/0 mice spontaneously develop mammary tumors by 150 days of age

endocrine/exocrine glands

decreased mammary gland tumor incidence ( J:282813 )

• at 150 days of age, mammary adenocarcinoma number is significantly lower than that in Tg(MMTV-PyVT)634Mul/0 mice and Nmral1^{Gt(S8-10A1)Sor}/Nmral1⁺ Tg(MMTV-PyVT)634Mul/0 mice

integument

decreased mammary gland tumor incidence ( J:282813 )

• at 150 days of age, mammary adenocarcinoma number is significantly lower than that in Tg(MMTV-PyVT)634Mul/0 mice and Nmral1^{Gt(S8-10A1)Sor}/Nmral1⁺ Tg(MMTV-PyVT)634Mul/0 mice

Genotype
MGI:3767793

cx16

• Allelic Composition: Nos2^tm1Lau/Nos2^tm1Lau; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: B6.Cg-Nos2^tm1Lau Tg(MMTV-PyVT)634Mul

neoplasm

abnormal tumor morphology ( J:121391 )

• Background Sensitivity: moderate rate of growth of tumors after reaching 1 cubic cm relative to FVB mice

decreased tumor incidence ( J:121391 )

• Background Sensitivity: fewer tumors develop than in FVB mice

increased tumor latency ( J:84218 , J:121391 )

• slower to develop mammary tumors (J:84218)

• delayed tumor development relative to FVB mice (J:84218)

• Background Sensitivity: delay in palpable tumor development of 3-4 weeks relative to mice on a FVB background (J:121391)

• Background Sensitivity: latency to tumors of 92 days (J:121391)

Genotype
MGI:3841377

cx17

• Allelic Composition: Adipoq^tm1Chan/Adipoq^tm1Chan; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: either: B6.Cg-Adipoq^tm1Chan Tg(MMTV-PyVT)634Mul or FVB.Cg-Adipoq^tm1Chan Tg(MMTV-PyVT)634Mul

mortality/aging

lethality throughout fetal growth and development, complete penetrance ( J:147458 )

• mice die during fetal development

Genotype
MGI:4436881

cx18

• Allelic Composition: Ctsb^tm1Jde/Ctsb^tm1Jde; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: FVB.129P2-Ctsb^tm1Jde Tg(MMTV-PyVT)634Mul

neoplasm

increased mammary gland tumor incidence ( J:157541 )

decreased metastatic potential ( J:157541 )

• form significantly less and shorter invasive strands in vitro compared with Tg(MMTV-PyVT)634Mul/0 controls

abnormal tumor morphology ( J:157541 )

• 56% of the tumors are poorly differentiated, compared with 75% of both Tg(MMTV-PyVT)634Mul/0 and Tg(MMTV-PyVT)634Mul/0; Ctsz^tm1Thre/Ctsz^tm1Thre tumors

• more of the tumors are well differentiated or moderately differentiated

decreased tumor growth/size ( J:157541 )

• tumor weight was reduced to 65%

increased tumor latency ( J:157541 )

• develop an average of five palpable tumors 4.5 days later than the Tg(MMTV-PyVT)634Mul/0 mice

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:157541 )

integument

increased mammary gland tumor incidence ( J:157541 )

Genotype
MGI:4436884

cx19

• Allelic Composition: Ctsb^tm1Jde/Ctsb^tm1Jde; Ctsz^tm1Thre/Ctsz^tm1Thre; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: FVB.129P2-Ctsz^tm1Thre Ctsb^tm1Jde Tg(MMTV-PyVT)634Mul

neoplasm

increased mammary gland tumor incidence ( J:157541 )

decreased metastatic potential ( J:157541 )

• 70% fewer lung metastases compared with Tg(MMTV-PyVT)634Mul/0 mice

• 80% smaller average metastasis size

• form significantly less and shorter invasive strands in vitro

abnormal tumor morphology ( J:157541 )

• 28% of the tumors are poorly differentiated, compared with 75% of both Tg(MMTV-PyVT)634Mul/0 and Tg(MMTV-PyVT)634Mul/0; Ctsz^tm1Thre/Ctsz^tm1Thre tumors

• more of the tumors are well differentiated or moderately differentiated

decreased tumor growth/size ( J:157541 )

• with nonpalpable and small tumors even at 14 weeks of age

• tumor weight is reduced to 45% compared with Tg(MMTV-PyVT)634Mul/0 mice

increased tumor latency ( J:157541 )

• develop an average of five palpable tumors 7.5 days later than the Tg(MMTV-PyVT)634Mul/0 mice

cellular

decreased apoptosis ( J:157541 )

• decreased TUNEL-positive cells compared with Ctsb^tm1Jde/Ctsb^tm1Jde;Tg(MMTV-PyVT)634Mul/0 mice

integument

increased mammary gland tumor incidence ( J:157541 )

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:157541 )

Genotype
MGI:4436882

cx20

• Allelic Composition: Ctsz^tm1Thre/Ctsz^tm1Thre; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: FVB.129P2-Ctsz^tm1Thre Tg(MMTV-PyVT)634Mul

neoplasm

increased mammary gland tumor incidence ( J:157541 )

decreased metastatic potential ( J:157541 )

• form significantly less and shorter invasive strands in vitro compared with Tg(MMTV-PyVT)634Mul/0 controls

increased tumor growth/size ( J:157541 )

• enlarged tumors at week 10 and 14 compared with Tg(MMTV-PyVT)634Mul/0 mice

• no difference in tumor weight at week 14

increased tumor latency ( J:157541 )

• develop an average of five palpable tumors 4.5 days later than the Tg(MMTV-PyVT)634Mul/0 mice

cellular

decreased apoptosis ( J:157541 )

• decreased TUNEL-positive cells compared with Tg(MMTV-PyVT)634Mul/0 mice and Ctsb^tm1Jde/ Ctsb^tm1Jde;Tg(MMTV-PyVT)634Mul/0 mice

integument

increased mammary gland tumor incidence ( J:157541 )

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:157541 )

Genotype
MGI:3841380

cx21

• Allelic Composition: Adipoq^tm1Chan/Adipoq⁺; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: FVB.Cg-Adipoq^tm1Chan Tg(MMTV-PyVT)634Mul

A basal-like subtype of mammary tumors in Adipoq^tm1Chan/Adipoq⁺ Tg(MMTV-PyVT)634Mul/0 mice

neoplasm

increased mammary gland tumor incidence ( J:147458 )

• mice develop mammary gland tumors with a median age of tumor latency of 58 days in females and 115 days in males compared to 66 days and 133.5 days in female and male Tg(MMTV-PyVT)634Mul mice, respectively

• mice develop tumors with a basal-like subtype

increased metastatic potential ( J:147458 )

• tumor cells implanted into nude mice exhibit increased proliferation and are more aggressive than tumor cells isolated from Tg(MMTV-PyVT)634Mul mice

• tumor cells from male mice exhibit increased metastatic capacity in nude mice compared to tumor cells from Tg(MMTV-PyVT)634Mul mice

abnormal tumor morphology ( J:147458 )

• proliferation of tumor-derived cells is more sensitive to adiponectin-mediated inhibition of cell proliferation than tumor cells from Tg(MMTV-PyVT)634Mul mice

increased tumor growth/size ( J:147458 )

• total wet weight of tumors is 2-fold heavier than in Tg(MMTV-PyVT)634Mul mice

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:147458 )

• mice develop mammary gland tumors with a median age of tumor latency of 58 days in females and 115 days in males compared to 66 days and 133.5 days in female and male Tg(MMTV-PyVT)634Mul mice, respectively

• mice develop tumors with a basal-like subtype

respiratory system

increased lung weight ( J:147458 )

integument

increased mammary gland tumor incidence ( J:147458 )

• mice develop mammary gland tumors with a median age of tumor latency of 58 days in females and 115 days in males compared to 66 days and 133.5 days in female and male Tg(MMTV-PyVT)634Mul mice, respectively

• mice develop tumors with a basal-like subtype

homeostasis/metabolism

decreased circulating adiponectin level ( J:147458 )

• 4- to 5-fold

growth/size/body

increased lung weight ( J:147458 )

Genotype
MGI:5649039

cx22

• Allelic Composition: Mtdh^Gt(XB780)Byg/Mtdh^Gt(XB780)Byg; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: FVB.Cg-Mtdh^Gt(XB780)Byg Tg(MMTV-PyVT)634Mul

neoplasm

decreased mammary gland tumor incidence ( J:214244 )

• total tumor burden is reduced to 10% of transgenic mice wild-type for Mtdh

abnormal tumor pathology ( J:214244 )

• isolated mammary epithelial cells from preneoplastic glands contain fewer tumor initiating cells

decreased metastatic potential ( J:214244 )

• mice have fewer and smaller metastatic nodules compared to transgenic mice wild-type for Mtdh

increased tumor latency ( J:214244 )

• mammary tumors are detected by 50 days of age and 50% of mice have tumors after 80 days of age, later than in transgenic mice wild-type for Mtdh

endocrine/exocrine glands

decreased mammary gland tumor incidence ( J:214244 )

• total tumor burden is reduced to 10% of transgenic mice wild-type for Mtdh

mammary gland hyperplasia ( J:214244 )

• display fewer and smaller hyperplastic foci at 4 weeks of age compared to transgenic mice wild-type for Mtdh

integument

decreased mammary gland tumor incidence ( J:214244 )

• total tumor burden is reduced to 10% of transgenic mice wild-type for Mtdh

mammary gland hyperplasia ( J:214244 )

• display fewer and smaller hyperplastic foci at 4 weeks of age compared to transgenic mice wild-type for Mtdh

Genotype
MGI:5649043

cx23

• Allelic Composition: Mtdh^Gt(XB780)Byg/Mtdh⁺; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: FVB.Cg-Mtdh^Gt(XB780)Byg Tg(MMTV-PyVT)634Mul

neoplasm

decreased mammary gland tumor incidence ( J:214244 )

• total tumor burden is reduced to 54% of transgenic mice wild-type for Mtdh

integument

decreased mammary gland tumor incidence ( J:214244 )

• total tumor burden is reduced to 54% of transgenic mice wild-type for Mtdh

endocrine/exocrine glands

decreased mammary gland tumor incidence ( J:214244 )

• total tumor burden is reduced to 54% of transgenic mice wild-type for Mtdh

Genotype
MGI:3767794

cx24

• Allelic Composition: Nos2^tm1Lau/Nos2^tm1Lau; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: FVB.Cg-Nos2^tm1Lau Tg(MMTV-PyVT)634Mul

neoplasm

increased tumor growth/size ( J:121391 )

• Background Sensitivity: exponential growth of tumors after reaching 1cubic cm

increased tumor incidence ( J:121391 )

• Background Sensitivity: more tumors appear than in mice on a B6 background

decreased tumor latency ( J:121391 )

• palpable tumor development is more rapid than in mice on a B6 background; latency to tumor appearance is ~53 days

Genotype
MGI:3804013

cx25

• Allelic Composition: Akt1^Gt1Pnt/Akt1^Gt1Pnt; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129 * C57BL/6 * FVB/N

neoplasm

increased mammary adenocarcinoma incidence ( J:117336 )

• female virgin mice develop mammary tumors by 45 weeks of age which is significantly later than in mice carrying the transgene on a wild-type background

• mice harbor fewer and smaller hyperplastic foci at 8 and 12 weeks of age compared to transgenic mice on a wild-type background

• at later ages, the hyperplastic foci are smaller in size than in the transgenic controls

• tumor growth in mammary glands is significantly slower than is found in transgenic mice on a wild-type background

• the percentage of proliferative cells found in early lesions of the mammary gland is half that found in transgenic mice on the wild-type background

• this decreased proliferation rate is not observed in later stages of tumor development

• both early lesions and advanced neoplasms have about double the percentage of apoptotic cells than is found in comparable tumors of transgenic mice on a wild-type background

• parenchymal metastases of breast adenocarcinomas are found in the lung

integument

increased mammary adenocarcinoma incidence ( J:117336 )

• female virgin mice develop mammary tumors by 45 weeks of age which is significantly later than in mice carrying the transgene on a wild-type background

• mice harbor fewer and smaller hyperplastic foci at 8 and 12 weeks of age compared to transgenic mice on a wild-type background

• at later ages, the hyperplastic foci are smaller in size than in the transgenic controls

• tumor growth in mammary glands is significantly slower than is found in transgenic mice on a wild-type background

• the percentage of proliferative cells found in early lesions of the mammary gland is half that found in transgenic mice on the wild-type background

• this decreased proliferation rate is not observed in later stages of tumor development

• both early lesions and advanced neoplasms have about double the percentage of apoptotic cells than is found in comparable tumors of transgenic mice on a wild-type background

• parenchymal metastases of breast adenocarcinomas are found in the lung

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:117336 )

• female virgin mice develop mammary tumors by 45 weeks of age which is significantly later than in mice carrying the transgene on a wild-type background

• mice harbor fewer and smaller hyperplastic foci at 8 and 12 weeks of age compared to transgenic mice on a wild-type background

• at later ages, the hyperplastic foci are smaller in size than in the transgenic controls

• tumor growth in mammary glands is significantly slower than is found in transgenic mice on a wild-type background

• the percentage of proliferative cells found in early lesions of the mammary gland is half that found in transgenic mice on the wild-type background

• this decreased proliferation rate is not observed in later stages of tumor development

• both early lesions and advanced neoplasms have about double the percentage of apoptotic cells than is found in comparable tumors of transgenic mice on a wild-type background

• parenchymal metastases of breast adenocarcinomas are found in the lung

Genotype
MGI:3804008

cx26

• Allelic Composition: Akt3^tm1Mbb/Akt3^tm1Mbb; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129 * C57BL/6 * FVB/N

neoplasm

increased mammary adenocarcinoma incidence ( J:117336 )

• female virgin mice develop mammary tumors by 17.5 weeks of age which is slightly but not significantly later than in mice carrying the transgene on a wild-type background

• parenchymal metastases of the tumors are found in the lung

integument

increased mammary adenocarcinoma incidence ( J:117336 )

• female virgin mice develop mammary tumors by 17.5 weeks of age which is slightly but not significantly later than in mice carrying the transgene on a wild-type background

• parenchymal metastases of the tumors are found in the lung

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:117336 )

• female virgin mice develop mammary tumors by 17.5 weeks of age which is slightly but not significantly later than in mice carrying the transgene on a wild-type background

• parenchymal metastases of the tumors are found in the lung

Genotype
MGI:3804011

cx27

• Allelic Composition: Akt2^tm1.1Mbb/Akt2^tm1.1Mbb; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129 * C57BL/6 * FVB/N

neoplasm

increased mammary adenocarcinoma incidence ( J:117336 )

• female virgin mice develop mammary tumors by 11 weeks of age which is significantly earlier than in mice carrying the transgene on a wild-type background

• parenchymal metastases of the tumors are found in the lung

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:117336 )

• female virgin mice develop mammary tumors by 11 weeks of age which is significantly earlier than in mice carrying the transgene on a wild-type background

• parenchymal metastases of the tumors are found in the lung

integument

increased mammary adenocarcinoma incidence ( J:117336 )

• female virgin mice develop mammary tumors by 11 weeks of age which is significantly earlier than in mice carrying the transgene on a wild-type background

• parenchymal metastases of the tumors are found in the lung

Genotype
MGI:5478601

cx28

• Allelic Composition: Cdcp1^tm1.2Moas/Cdcp1^tm1.2Moas; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129 * C57BL/6 * FVB/N * SJL

mortality/aging

decreased tumor-free survival time ( J:194368 )

• mice are euthanized at 12 weeks due to numerous large tumors

neoplasm

increased tumor growth/size ( J:194368 )

• accelerated tumorigenesis compared with Tg(MMTV-PyVT)634Mul mice

increased tumor incidence ( J:194368 )

• at 12 weeks mice exhibit a 2.6-fold increase in the number of tumors per mouse with an average of 5.7-fold increase in total tumor burden compared with Tg(MMTV-PyVT)634Mul mice

• with lung metastases

Genotype
MGI:5478603

cx29

• Allelic Composition: Cdcp1^tm1.2Moas/Cdcp1⁺; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129 * C57BL/6 * FVB/N * SJL

neoplasm

increased tumor incidence ( J:194368 )

• slight compared with Tg(MMTV-PyVT)634Mul mice

Genotype
MGI:3690443

cx30

• Allelic Composition: Plg^tm1Jld/Plg^tm1Jld; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129P2/OlaHsd * Black Swiss * FVB/N

neoplasm

increased mammary adenocarcinoma incidence ( J:48285 )

• develop mammary tumors within 99 days after birth similar to those seen in Tg(MMTV-PyVT)634Mul mutants

decreased metastatic potential ( J:48285 )

• exhibit significantly reduced lung metastasis with respect to frequency of occurrence, total number of metastases, and total metastatic tumor burden, compared with Tg(MMTV-PyVT)634Mul mutants

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:48285 )

• develop mammary tumors within 99 days after birth similar to those seen in Tg(MMTV-PyVT)634Mul mutants

integument

increased mammary adenocarcinoma incidence ( J:48285 )

• develop mammary tumors within 99 days after birth similar to those seen in Tg(MMTV-PyVT)634Mul mutants

Genotype
MGI:4943925

cx31

• Allelic Composition: Cd44^tm1Mak/Cd44^tm1Mak; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * FVB/N

neoplasm

increased metastatic potential ( J:100774 )

• an increase in the percentage of mice developing metastases at 14 weeks, compared with Cd44^tm1Mak/+, Tg(MMTV-PyVT)634Mul mice

• a greater number of metastases per lung

• similar tumor onset or size in breast

• similar hyaluronan deposition in the pulmonary metastases

Genotype
MGI:5527556

cx32

• Allelic Composition: Flot2^tm1Mak/Flot2^tm1Mak; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * FVB/N

mortality/aging

premature death ( J:203238 )

• as in Tg(MMTV-PyVT)634Mul mice

neoplasm

increased mammary gland tumor incidence ( J:203238 )

• as in Tg(MMTV-PyVT)634Mul mice

decreased metastatic potential ( J:203238 )

• 10-fold fewer visible macro-metastases in the lungs compared to in Tg(MMTV-PyVT)634Mul mice

• fewer micro-metastases in the lungs compared to in Tg(MMTV-PyVT)634Mul mice

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:203238 )

• as in Tg(MMTV-PyVT)634Mul mice

integument

increased mammary gland tumor incidence ( J:203238 )

• as in Tg(MMTV-PyVT)634Mul mice

Genotype
MGI:4429454

cx33

• Allelic Composition: Fgfr4^tm1Axul/Fgfr4^tm1Axul; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * FVB/N

neoplasm

abnormal tumor susceptibility ( J:156750 )

• no difference in tumor size compared to Tg alone

Genotype
MGI:5485071

cx34

• Allelic Composition: Ptk2^tm3.1Guan/Ptk2^tm3.1Guan; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6J * FVB/N

Suppressed mammary tumor growth in Ptk2^tm3.1Guan/Ptk2^tm3.1Guan Tg(MMTV-PyVT)634Mul/0 mice

neoplasm

decreased metastatic potential ( J:195658 )

• fewer metastatic nodules than in Ptk2^tm3.1Guan/Ptk2⁺ Tg(MMTV-PyVT)634Mul mice

abnormal tumor morphology ( J:195658 )

• tumor cells exhibit defective epithelial-mesenchymal transition and fewer mammary cancer stem cells compared to in Ptk2^tm3.1Guan/Ptk2⁺ Tg(MMTV-PyVT)634Mul mice

decreased tumor growth/size ( J:195658 )

• tumors grow slower than in Ptk2^tm3.1Guan/Ptk2⁺ Tg(MMTV-PyVT)634Mul mice

Genotype
MGI:6472861

cx35

• Allelic Composition: Kars1^{Gt(AJ0130)Wtsi}/Kars1⁺; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

neoplasm

decreased metastatic potential ( J:264950 )

♀ • mice exhibit a lower incidence of lung metastasis than control mice carrying the transgene on a wild-type background, as determined by counting metastatic lung nodules in female mice at 16 or 18 weeks of age

Genotype
MGI:3613521

cx36

• Allelic Composition: Rhoc^tm1Mak/Rhoc^tm1Mak; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

neoplasm

increased mammary adenocarcinoma incidence ( J:100482 )

• no differences are observed in frequency, size or latency of primary tumor appearance compared to mice carrying only the transgene

• tumor angiogenesis, tumor cell proliferation and apoptosis are likewise similar to mice carrying only the transgene

decreased metastatic potential ( J:100482 )

• significantly reduced numbers of pulmonary metastases are present in the mutant mice

• pulmonary metastases are also reduced in size compared to mice carrying only the transgene

• in vitro, tumor cells derived from mutant mice have reduced migration and invasiveness, and in vivo, metastatic cells appeared to exhibit increased apoptosis

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:100482 )

• no differences are observed in frequency, size or latency of primary tumor appearance compared to mice carrying only the transgene

• tumor angiogenesis, tumor cell proliferation and apoptosis are likewise similar to mice carrying only the transgene

integument

increased mammary adenocarcinoma incidence ( J:100482 )

• no differences are observed in frequency, size or latency of primary tumor appearance compared to mice carrying only the transgene

• tumor angiogenesis, tumor cell proliferation and apoptosis are likewise similar to mice carrying only the transgene

Genotype
MGI:4367709

cx37

• Allelic Composition: Mmp7^tm1Lmm/Mmp7^tm1Lmm; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:140033 )

• development of mammary gland tumors and metastasis to the lungs are similar to in Tg(MMTV-PyVT)634Mul mice

integument

increased mammary gland tumor incidence ( J:140033 )

• development of mammary gland tumors and metastasis to the lungs are similar to in Tg(MMTV-PyVT)634Mul mice

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:140033 )

• development of mammary gland tumors and metastasis to the lungs are similar to in Tg(MMTV-PyVT)634Mul mice

Genotype
MGI:3581867

cx38

• Allelic Composition: Fes^tm1Pag/Fes^tm1Pag; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * CD-1

neoplasm

decreased tumor latency ( J:98281 )

• tumor onset and initiation of the rapid growth phase of tumor development occur earlier compared to transgenic mice that are wild-type for Fes but later than in transgenic mice homozygous for Fes^tm2Pag

Genotype
MGI:3581866

cx39

• Allelic Composition: Fes^tm2Pag/Fes^tm2Pag; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * CD-1

neoplasm

decreased tumor latency ( J:98281 )

• tumor onset and initiation of the rapid growth phase of tumor development occur earlier compared to transgenic mice that are wild-type for Fes or homozygous for Fes^tm1Pag

Genotype
MGI:4361928

cx40

• Allelic Composition: Shc1^tm5Paw/Shc1⁺; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:133325 )

• tumor nodules are present throughout the entire mammary gland

• combination of adenomas and cystic hyperplasias are seen in mammary glands

decreased metastatic potential ( J:133325 )

• number of mice displaying lung metastases is decreased compared to Tg(MMTV-PyVT)634Mul single mutants (53 vs 91 mice)

increased tumor latency ( J:133325 )

• mammary tumor onset is modestly delayed compared to Tg(MMTV-PyVT)634Mul single mutants (81 days vs 66 days)

endocrine/exocrine glands

abnormal mammary gland morphology ( J:133325 )

♀ • tumor nodules are present throughout the entire mammary gland

increased mammary gland tumor incidence ( J:133325 )

• tumor nodules are present throughout the entire mammary gland

• combination of adenomas and cystic hyperplasias are seen in mammary glands

integument

abnormal mammary gland morphology ( J:133325 )

♀ • tumor nodules are present throughout the entire mammary gland

increased mammary gland tumor incidence ( J:133325 )

• tumor nodules are present throughout the entire mammary gland

• combination of adenomas and cystic hyperplasias are seen in mammary glands

Genotype
MGI:2679599

cx41

• Allelic Composition: Grb2^tm1Paw/Grb2⁺; Tg(MMTV-PyVT)634Mul/?
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * FVB/N

neoplasm

increased mammary adenocarcinoma incidence ( J:51424 )

• delayed onset of mammary tumorigenesis compared to wild-type Grb2 mice carrying transgene

integument

increased mammary adenocarcinoma incidence ( J:51424 )

• delayed onset of mammary tumorigenesis compared to wild-type Grb2 mice carrying transgene

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:51424 )

• delayed onset of mammary tumorigenesis compared to wild-type Grb2 mice carrying transgene

Genotype
MGI:4361926

cx42

• Allelic Composition: Shc1^tm7Paw/Shc1⁺; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:133325 )

• glands contain combination of tumor and hyperplastic structures

• combination of adenomas and cystic hyperplasias are seen in mammary glands

• tumor angiogenesis is decreased relative to tumors from Tg(MMTV-PyVT)634Mul single mutants

decreased metastatic potential ( J:133325 )

• number of mice displaying lung metastases is decreased compared to Tg(MMTV-PyVT)634Mul single mutants (60 vs 91 mice)

increased tumor latency ( J:133325 )

• mammary tumor latency is strongly increased compared to Tg(MMTV-PyVT)634Mul single mutants (95 days vs 66 days)

endocrine/exocrine glands

abnormal mammary gland morphology ( J:133325 )

♀ • glands contain combination of tumor and hyperplastic structures

increased mammary gland tumor incidence ( J:133325 )

• glands contain combination of tumor and hyperplastic structures

• combination of adenomas and cystic hyperplasias are seen in mammary glands

• tumor angiogenesis is decreased relative to tumors from Tg(MMTV-PyVT)634Mul single mutants

integument

abnormal mammary gland morphology ( J:133325 )

♀ • glands contain combination of tumor and hyperplastic structures

increased mammary gland tumor incidence ( J:133325 )

• glands contain combination of tumor and hyperplastic structures

• combination of adenomas and cystic hyperplasias are seen in mammary glands

• tumor angiogenesis is decreased relative to tumors from Tg(MMTV-PyVT)634Mul single mutants

Genotype
MGI:4361927

cx43

• Allelic Composition: Shc1^tm6Paw/Shc1⁺; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:133325 )

• tumor nodules are present throughout the entire mammary gland

• combination of adenomas and cystic hyperplasias are seen in mammary glands

• tumor angiogenesis assessed by microvessel density is significantly decreaed relative to tumors from Tg(MMTV-PyVT)634Mul single mutants, along with increased level of ischemic necrosis

decreased metastatic potential ( J:133325 )

• number of mice displaying lung metastases is decreased compared to Tg(MMTV-PyVT)634Mul single mutants (58 vs 91 mice)

increased tumor latency ( J:133325 )

• mammary tumor onset is modestly delayed compared to Tg(MMTV-PyVT)634Mul single mutants (86 days vs 66 days)

endocrine/exocrine glands

abnormal mammary gland morphology ( J:133325 )

♀ • tumor nodules are present throughout the entire mammary gland

♀ • combination of adenomas and cystic hyperplasias are seen in mammary glands

increased mammary gland tumor incidence ( J:133325 )

• tumor nodules are present throughout the entire mammary gland

• combination of adenomas and cystic hyperplasias are seen in mammary glands

• tumor angiogenesis assessed by microvessel density is significantly decreaed relative to tumors from Tg(MMTV-PyVT)634Mul single mutants, along with increased level of ischemic necrosis

integument

abnormal mammary gland morphology ( J:133325 )

♀ • tumor nodules are present throughout the entire mammary gland

♀ • combination of adenomas and cystic hyperplasias are seen in mammary glands

increased mammary gland tumor incidence ( J:133325 )

• tumor nodules are present throughout the entire mammary gland

• combination of adenomas and cystic hyperplasias are seen in mammary glands

• tumor angiogenesis assessed by microvessel density is significantly decreaed relative to tumors from Tg(MMTV-PyVT)634Mul single mutants, along with increased level of ischemic necrosis

Genotype
MGI:4361929

cx44

• Allelic Composition: Shc1^tm5Paw/Shc1^tm5Paw; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:133325 )

• cells of hyperplastic lesions show a significant reduction of percentage of proliferating cells but no drastic increase in apoptotic cell number in mammary glands of 8-week old females

• tumor angiogenesis assessed by microvessel density is significantly decreaed relative to tumors from Tg(MMTV-PyVT)634Mul single mutants, along with increased level of ischemic necrosis

decreased metastatic potential ( J:133325 )

• number of mice displaying lung metastases is decreased by greater than 3-fold compared to Tg(MMTV-PyVT)634Mul single mutants (24 vs 91 mice)

increased tumor latency ( J:133325 )

• mammary tumor latency is strongly increased compared to Tg(MMTV-PyVT)634Mul single mutants (155 days vs 66 days)

endocrine/exocrine glands

abnormal mammary gland morphology ( J:133325 )

♀ • entire gland is hyperplastic

♀ • mammary glands are composed of single layer of epithelial cells surrounding a dilated lumen

increased mammary gland tumor incidence ( J:133325 )

• cells of hyperplastic lesions show a significant reduction of percentage of proliferating cells but no drastic increase in apoptotic cell number in mammary glands of 8-week old females

• tumor angiogenesis assessed by microvessel density is significantly decreaed relative to tumors from Tg(MMTV-PyVT)634Mul single mutants, along with increased level of ischemic necrosis

integument

abnormal mammary gland morphology ( J:133325 )

♀ • entire gland is hyperplastic

♀ • mammary glands are composed of single layer of epithelial cells surrounding a dilated lumen

increased mammary gland tumor incidence ( J:133325 )

• cells of hyperplastic lesions show a significant reduction of percentage of proliferating cells but no drastic increase in apoptotic cell number in mammary glands of 8-week old females

• tumor angiogenesis assessed by microvessel density is significantly decreaed relative to tumors from Tg(MMTV-PyVT)634Mul single mutants, along with increased level of ischemic necrosis

Genotype
MGI:4361930

cx45

• Allelic Composition: Shc1^tm6Paw/Shc1^tm6Paw; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:133325 )

• tumor nodules are present throughout the entire mammary gland

• lesions eventually progress to carcinoma

• tumors are highly apoptotic compared to tumors from Tg(MMTV-PyVT)634Mul single mutants

• tumor angiogenesis is decreased relative to tumors from Tg(MMTV-PyVT)634Mul single mutants

decreased metastatic potential ( J:133325 )

• number of mice displaying lung metastases is decreased about 3-fold compared to Tg(MMTV-PyVT)634Mul single mutants (30 vs 91 mice)

increased tumor latency ( J:133325 )

• mammary tumor latency is strongly increased compared to Tg(MMTV-PyVT)634Mul single mutants (132 days vs 66 days)

endocrine/exocrine glands

abnormal mammary gland morphology ( J:133325 )

♀ • entire gland is hyperplastic

♀ • mammary glands are composed of single layer of epithelial cells surrounding a dilated lumen

increased mammary gland tumor incidence ( J:133325 )

• tumor nodules are present throughout the entire mammary gland

• lesions eventually progress to carcinoma

• tumors are highly apoptotic compared to tumors from Tg(MMTV-PyVT)634Mul single mutants

• tumor angiogenesis is decreased relative to tumors from Tg(MMTV-PyVT)634Mul single mutants

integument

abnormal mammary gland morphology ( J:133325 )

♀ • entire gland is hyperplastic

♀ • mammary glands are composed of single layer of epithelial cells surrounding a dilated lumen

increased mammary gland tumor incidence ( J:133325 )

• tumor nodules are present throughout the entire mammary gland

• lesions eventually progress to carcinoma

• tumors are highly apoptotic compared to tumors from Tg(MMTV-PyVT)634Mul single mutants

• tumor angiogenesis is decreased relative to tumors from Tg(MMTV-PyVT)634Mul single mutants

Genotype
MGI:2680919

cx46

• Allelic Composition: Ets2^tm1Rgo/Ets2⁺; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129S2/SvPas * Black Swiss * FVB/N

neoplasm

decreased tumor growth/size ( J:57272 )

• reduced size of mammary tumors relative to controls

• correlated with a more differentiated state of early hyperplastic growths

Genotype
MGI:4367707

cx47

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:140033 )

• development of mammary gland tumors is similar to in Tg(MMTV-PyVT)634Mul mice

decreased metastatic potential ( J:140033 )

• Background Sensitivity: mice exhibit reduced lung metastasis compared with Tg(MMTV-PyVT)634Mul mice unlike on a background lacking C57BL/6 with an 80% reduction in surface tumor number, a 76% reduction in total tumor area, and a slight reduction in average tumor size

abnormal tumor morphology ( J:140033 )

• metastatic lung tumors exhibit decreased staining for blood vessels compared with equivalent tumors in Tg(MMTV-PyVT)634Mul mice

decreased tumor growth/size ( J:140033 )

• proliferation and apoptosis rates of metastatic tumor cells are decreased compared with cells from Tg(MMTV-PyVT)634Mul mice with the balance resulting in reduced tumor size

integument

increased mammary gland tumor incidence ( J:140033 )

• development of mammary gland tumors is similar to in Tg(MMTV-PyVT)634Mul mice

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:140033 )

• development of mammary gland tumors is similar to in Tg(MMTV-PyVT)634Mul mice

Genotype
MGI:4367708

cx48

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129S6/SvEvTac * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:140033 )

• Background Sensitivity: development of mammary gland tumors and metastasis are similar to in Tg(MMTV-PyVT)634Mul mice unlike on a background containing C57BL/6

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:140033 )

• Background Sensitivity: development of mammary gland tumors and metastasis are similar to in Tg(MMTV-PyVT)634Mul mice unlike on a background containing C57BL/6

integument

increased mammary gland tumor incidence ( J:140033 )

• Background Sensitivity: development of mammary gland tumors and metastasis are similar to in Tg(MMTV-PyVT)634Mul mice unlike on a background containing C57BL/6

Genotype
MGI:6093700

cx49

• Allelic Composition: Tgfb1i1^tm1.2Cet/Tgfb1i1^tm1.2Cet; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129S/SvEv * C57BL/6 * FVB/N

neoplasm

decreased mammary gland tumor incidence ( J:241234 )

♀ • onset of palpable mammary tumor formation is slightly delayed and growth of the primary tumor is reduced compared to control heterozygous Tgfb1i1^tm1.1Cet Tg(MMTV-PyVT)634Mul mice

♀ • tumor stroma contains fewer cancer-associated fibroblasts and reduced extracellular matrix deposition

♀ • isolated cancer-associated fibroblasts are defective in stress fiber organization and exhibit reduced contractility

♀ • more than 2-fold reduction in the number of proliferating cells in mammary tumors

decreased metastatic potential ( J:241234 )

♀ • mammary tumors exhibit fewer lung metastases than controls

endocrine/exocrine glands

decreased mammary gland tumor incidence ( J:241234 )

♀ • onset of palpable mammary tumor formation is slightly delayed and growth of the primary tumor is reduced compared to control heterozygous Tgfb1i1^tm1.1Cet Tg(MMTV-PyVT)634Mul mice

♀ • tumor stroma contains fewer cancer-associated fibroblasts and reduced extracellular matrix deposition

♀ • isolated cancer-associated fibroblasts are defective in stress fiber organization and exhibit reduced contractility

♀ • more than 2-fold reduction in the number of proliferating cells in mammary tumors

integument

decreased mammary gland tumor incidence ( J:241234 )

♀ • onset of palpable mammary tumor formation is slightly delayed and growth of the primary tumor is reduced compared to control heterozygous Tgfb1i1^tm1.1Cet Tg(MMTV-PyVT)634Mul mice

♀ • tumor stroma contains fewer cancer-associated fibroblasts and reduced extracellular matrix deposition

♀ • isolated cancer-associated fibroblasts are defective in stress fiber organization and exhibit reduced contractility

♀ • more than 2-fold reduction in the number of proliferating cells in mammary tumors

Genotype
MGI:4352683

cx50

• Allelic Composition: Map3k1^tm1Glj/Map3k1^tm1Glj; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129S/SvEv * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:112298 )

• mice develop palpable mammary tumors at a similar rate and multiplicity as in Tg(MMTV-PyVT)634Mul mice

decreased metastatic potential ( J:112298 )

• by 16 weeks only 25% of mice develop metastasis to the lungs compared to 75% of Tg(MMTV-PyVT)634Mul mice

• inhibited metastatic potential is due to inhibition of tumor cells to disseminate from the source

• however, the ability of cells to establish lung metastasis is normal

abnormal tumor morphology ( J:112298 )

• tumor cell gelatinase activity is decreased compared to in tumors cells from heterozygous mice

• tumor basement membrane integrity is prolonged compared to in tumors from heterozygous mice

• mice exhibit the same tumor growth, progression to an invasive phenotype, and vascularization as in Tg(MMTV-PyVT)634Mul mice

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:112298 )

• mice develop palpable mammary tumors at a similar rate and multiplicity as in Tg(MMTV-PyVT)634Mul mice

integument

increased mammary gland tumor incidence ( J:112298 )

• mice develop palpable mammary tumors at a similar rate and multiplicity as in Tg(MMTV-PyVT)634Mul mice

Genotype
MGI:4417966

cx51

• Allelic Composition: Cav1^tm1Mls/Cav1⁺; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129/Sv * C57BL/6J * FVB/N * SJL

neoplasm

increased mammary gland tumor incidence ( J:132472 )

• mutants develop dysplastic mammary lesions to a similar extent as observed in single hemizygous Tg(MMTV-PyVT)634Mul mice

integument

increased mammary gland tumor incidence ( J:132472 )

• mutants develop dysplastic mammary lesions to a similar extent as observed in single hemizygous Tg(MMTV-PyVT)634Mul mice

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:132472 )

• mutants develop dysplastic mammary lesions to a similar extent as observed in single hemizygous Tg(MMTV-PyVT)634Mul mice

Genotype
MGI:4417965

cx52

• Allelic Composition: Cav1^tm1Mls/Cav1^tm1Mls; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129/Sv * C57BL/6J * FVB/N * SJL

neoplasm

increased mammary gland tumor incidence ( J:132472 )

• development of mulifocal dysplastic mammary lesions is accelerated compared to single hemizygous Tg(MMTV-PyVT)634Mul mice; 2-fold increase in the number of lesions and 5-6-fold increase in the total area occupied by the lesions at 3 weeks of age

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:132472 )

• development of mulifocal dysplastic mammary lesions is accelerated compared to single hemizygous Tg(MMTV-PyVT)634Mul mice; 2-fold increase in the number of lesions and 5-6-fold increase in the total area occupied by the lesions at 3 weeks of age

integument

increased mammary gland tumor incidence ( J:132472 )

• development of mulifocal dysplastic mammary lesions is accelerated compared to single hemizygous Tg(MMTV-PyVT)634Mul mice; 2-fold increase in the number of lesions and 5-6-fold increase in the total area occupied by the lesions at 3 weeks of age

Genotype
MGI:5547962

cx53

• Allelic Composition: Atf3^tm1Dron/Atf3^tm1Dron; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * FVB/N

neoplasm

decreased metastatic potential ( J:201626 )

• reduced lung metastasis compared to in Tg(MMTV-PyVT)634Mul mice

decreased tumor growth/size ( J:201626 )

• reduced primary tumor volume compared to in Tg(MMTV-PyVT)634Mul mice

Genotype
MGI:5827714

cx54

• Allelic Composition: Inpp5j^tm1.1Cmit/Inpp5j^tm1.1Cmit; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6

neoplasm

increased mammary gland tumor incidence ( J:224914 )

• total mammary tumor burden is significantly increased relative to that in control mice carrying the transgene on a wild-type background

abnormal tumor pathology ( J:224914 )

• mice show significantly enhanced primary mammary cancer initiation and tumor progression relative to control mice

• tumors show increased AKT signaling

decreased metastatic potential ( J:224914 )

• mice show a 4.3-fold reduction in the total number of lung metastases relative to control mice

increased tumor growth/size ( J:224914 )

• mean volume of the largest mammary tumor per mouse and total tumor volume is significantly higher than that in control mice, and associated with increased cell proliferation as shown by Ki67 staining

cellular

decreased cell migration ( J:224914 )

• in transwell assays, epithelial tumor cells established from primary mammary tumors show a 3.5-fold decrease in relative cell migration toward a serum gradient; cell migration defect is partly rescued by treatment with a pan-AKT inhibitor (AktX), suggesting dysregulated AKT signaling

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:224914 )

• total mammary tumor burden is significantly increased relative to that in control mice carrying the transgene on a wild-type background

mammary gland hyperplasia ( J:224914 )

• at 45 days of age, mice show a ~5-fold increase in the number of hyperplastic foci in mammary fat pads relative to control mice carrying the transgene on a wild-type background

• total area of mammary gland hyperplasia is increased by 3-fold at 45 days and by 2.4-fold at 70 days of age

• % of proliferating (Ki67+) cells is significantly increased in hyperplastic lesions at 45 and 70 days of age

integument

increased mammary gland tumor incidence ( J:224914 )

• total mammary tumor burden is significantly increased relative to that in control mice carrying the transgene on a wild-type background

mammary gland hyperplasia ( J:224914 )

• at 45 days of age, mice show a ~5-fold increase in the number of hyperplastic foci in mammary fat pads relative to control mice carrying the transgene on a wild-type background

• total area of mammary gland hyperplasia is increased by 3-fold at 45 days and by 2.4-fold at 70 days of age

• % of proliferating (Ki67+) cells is significantly increased in hyperplastic lesions at 45 and 70 days of age

Genotype
MGI:5902964

cx55

• Allelic Composition: Ube2o^{tm1.1(KOMP)Mbp}/Ube2o⁺; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6 * C57BL/6N * FVB/N

mortality/aging

increased tumor-free survival time ( J:239679 )

• mice exhibit extended survival compared with Tg(MMTV-PyVT)634Mul mice

neoplasm

decreased tumor growth/size ( J:239679 )

• reduced tumor size and weight of mammary glands compared with Tg(MMTV-PyVT)634Mul mice

increased tumor latency ( J:239679 )

• compared with Tg(MMTV-PyVT)634Mul mice

Genotype
MGI:5902963

cx56

• Allelic Composition: Ube2o^{tm1.1(KOMP)Mbp}/Ube2o^{tm1.1(KOMP)Mbp}; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6 * C57BL/6N * FVB/N

mortality/aging

increased tumor-free survival time ( J:239679 )

• mice exhibit extended survival compared with Tg(MMTV-PyVT)634Mul mice

neoplasm

decreased tumor growth/size ( J:239679 )

• reduced tumor size and weight of mammary glands compared with Tg(MMTV-PyVT)634Mul mice

• 7 of 13 mice exhibit no tumors

increased tumor latency ( J:239679 )

• compared with Tg(MMTV-PyVT)634Mul mice

endocrine/exocrine glands

mammary gland hypoplasia ( J:239679 )

• non-malignant

integument

mammary gland hypoplasia ( J:239679 )

• non-malignant

Genotype
MGI:5608671

cx57

• Allelic Composition: Rhoj^tm1.2Auem/Rhoj^tm1.2Auem; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6 * CBA/JNCrlj * FVB/N

neoplasm

abnormal tumor vascularization ( J:208154 )

♀ • decreased tumor vascular densities and vascular sprouting in peri- and intratumoral regions

♀ • vascular morphology in intratumoral regions appear more disrupted, vascular permeability is increased and pericyte support is reduced

decreased mammary gland tumor incidence ( J:208154 )

♀ • decreased development of spontaneous mammary tumor nodules at 14 weeks of age and median time to palpable tumor development is delayed by approximately 2 weeks

decreased metastatic potential ( J:208154 )

♀ • average number of metastatic tumor colonies in the lung is reduced

decreased tumor growth/size ( J:208154 )

♀ • average tumor size is reduced

♀ • tumor progression and invasion is delayed

homeostasis/metabolism

delayed wound healing ( J:208154 )

• 23% delayed wound closure, 48% reduced vascular density and 39% decreased granulation area in wound regions in a punch wound healing assay

cardiovascular system

abnormal tumor vascularization ( J:208154 )

♀ • decreased tumor vascular densities and vascular sprouting in peri- and intratumoral regions

♀ • vascular morphology in intratumoral regions appear more disrupted, vascular permeability is increased and pericyte support is reduced

endocrine/exocrine glands

decreased mammary gland tumor incidence ( J:208154 )

♀ • decreased development of spontaneous mammary tumor nodules at 14 weeks of age and median time to palpable tumor development is delayed by approximately 2 weeks

integument

decreased mammary gland tumor incidence ( J:208154 )

♀ • decreased development of spontaneous mammary tumor nodules at 14 weeks of age and median time to palpable tumor development is delayed by approximately 2 weeks

Genotype
MGI:3809817

cx58

• Allelic Composition: Cdh13^tm1Brns/Cdh13^tm1Brns; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6 * FVB/N

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:132759 )

• unlike in wild-type mice or Cdh13^tm1Brns homozygotes

mortality/aging

mortality/aging ( J:132759 )

N • mice exhibit an 18.5 day increase in average survival time compared to in Tg(MMTV-PyVT)634Mul mice

neoplasm

abnormal tumor vascularization ( J:132759 )

• tumors exhibit decreased neovscularization compared to in Tg(MMTV-PyVT)634Mul mice

increased mammary gland tumor incidence ( J:132759 )

• unlike in wild-type mice or Cdh13^tm1Brns homozygotes

increased metastatic potential ( J:132759 )

• all tumors exhibit pulmonary metastases unlike in Tg(MMTV-PyVT)634Mul mice

abnormal tumor morphology ( J:132759 )

• tumor endothelial cell density is reduced 31% and vessel branching is reduced 45% compared to in Tg(MMTV-PyVT)634Mul mice

• tumors exhibit a 6-fold increase in apoptosis and a 3-fold increase in oxygen-deprived areas compared to in Tg(MMTV-PyVT)634Mul mice

• tumors exhibit decreased neovscularization compared to in Tg(MMTV-PyVT)634Mul mice

• tumor incidence, diversity and differentiation are reduced compared to in Tg(MMTV-PyVT)634Mul mice

• when mice were transplanted with Tg(MMTV-PyVT)634Mul mice or Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul tumors, the weight of the tumors is reduced compared to when they are transplanted into wild-type mice

• adiponectin staining of tumors is reduced compared to in Tg(MMTV-PyVT)634Mul mice

• tumor proliferation is the same as in Tg(MMTV-PyVT)634Mul mice

decreased tumor growth/size ( J:132759 )

• mice exhibit a 3-fold reduction in the area covered by mammary tumors compared to in Tg(MMTV-PyVT)634Mul mice

decreased incidence of induced tumors ( J:132759 )

• mice exhibit a 10 day delay in mammary tumor onset, a 3-fold reduction in the area covered by mammary tumors and an 18.5 day increase in average survival time compared to in Tg(MMTV-PyVT)634Mul mice

integument

increased mammary gland tumor incidence ( J:132759 )

• unlike in wild-type mice or Cdh13^tm1Brns homozygotes

cardiovascular system

abnormal tumor vascularization ( J:132759 )

• tumors exhibit decreased neovscularization compared to in Tg(MMTV-PyVT)634Mul mice

Genotype
MGI:3841457

cx59

• Allelic Composition: Ksr1^tm1Shaw/Ksr1^tm1Shaw; Tg(MMTV-PyVT)634Mul/?
• Genetic Background: involves: C57BL/6 * FVB/N

neoplasm

increased tumor latency ( J:75739 )

• onset of tumor formation is delayed with no mammary tumors detected until 65 +/- 9 days of age compared to 35 +/- 8 days of age for heterozygous controls

Genotype
MGI:6696447

cx60

• Allelic Composition: Myct1^em1Choi/Myct1^em1Choi; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6 * FVB/N

neoplasm

abnormal tumor vascularization ( J:303692 )

• mammary gland tumors show reduced counts of tumor vessels and better pericyte coverage

decreased mammary gland tumor incidence ( J:303692 )

• mice show retarded mammary gland tumor growth compared to single Tg(MMTV-PyVT)634Mul transgenics, with tumors showing reduced counts of tumor vessels and better pericyte coverage

• mice show subsided intratumoral hypoxia

cardiovascular system

abnormal tumor vascularization ( J:303692 )

• mammary gland tumors show reduced counts of tumor vessels and better pericyte coverage

endocrine/exocrine glands

decreased mammary gland tumor incidence ( J:303692 )

• mice show retarded mammary gland tumor growth compared to single Tg(MMTV-PyVT)634Mul transgenics, with tumors showing reduced counts of tumor vessels and better pericyte coverage

• mice show subsided intratumoral hypoxia

integument

decreased mammary gland tumor incidence ( J:303692 )

• mice show retarded mammary gland tumor growth compared to single Tg(MMTV-PyVT)634Mul transgenics, with tumors showing reduced counts of tumor vessels and better pericyte coverage

• mice show subsided intratumoral hypoxia

Genotype
MGI:7859290

cx61

• Allelic Composition: Ak6^tm1.1Zhexf/Ak6⁺; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6 * FVB/N

neoplasm

decreased mammary gland tumor incidence ( J:241160 )

• at 120 days of age only 40% (2 of 5) of mice have tumors compared to tumors present in all controls (transgenic mice wild-type for Ak6) by 70 days of age

increased tumor latency ( J:241160 )

• breast tumors start developing at 90 days of age compared to 70 days of age in transgenic mice wild-type for Ak6

endocrine/exocrine glands

decreased mammary gland tumor incidence ( J:241160 )

• at 120 days of age only 40% (2 of 5) of mice have tumors compared to tumors present in all controls (transgenic mice wild-type for Ak6) by 70 days of age

integument

decreased mammary gland tumor incidence ( J:241160 )

• at 120 days of age only 40% (2 of 5) of mice have tumors compared to tumors present in all controls (transgenic mice wild-type for Ak6) by 70 days of age

Genotype
MGI:6358371

cx62

• Allelic Composition: Mir31^em1Nju/Mir31^em1Nju; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6J * FVB/N

mortality/aging

extended life span ( J:271420 )

♀ • overall survival time is longer than in single Tg(MMTV-PyVT)634Mul transgenic mice with mice showing a higher metastasis-free survival rate

neoplasm

decreased mammary gland tumor incidence ( J:271420 )

♀ • development of primary mammary lesions is suppressed at 12 and 16 weeks of age compared to single Tg(MMTV-PyVT)634Mul transgenic mice

♀ • tumors do not show malignant features and appear more like benign adenomas

♀ • the number of proliferating cells is much lower in tumors

♀ • marker analysis indicates a basal-to-luminal cell fate change in mammary tumor cells

♀ • reduction in the percentage of the CD24+CD90+ cancer stem cell population in mammary tumors compared to Tg(MMTV-PyVT)634Mul tumors

♀ • limiting-dilution transplantation assays indicate that tumor cells show an approximate 13-fold decrease in tumor-initiating ability

decreased metastatic potential ( J:271420 )

♀ • mice show a reduction in metastatic foci in lungs compared to single Tg(MMTV-PyVT)634Mul transgenic mice

♀ • mice show a higher metastasis-free survival rate compared to single Tg(MMTV-PyVT)634Mul transgenic mice

decreased tumor growth/size ( J:271420 )

♀ • at 20 weeks of age, mammary gland tumors are much smaller than in single Tg(MMTV-PyVT)634Mul transgenic mice

endocrine/exocrine glands

decreased mammary gland tumor incidence ( J:271420 )

♀ • development of primary mammary lesions is suppressed at 12 and 16 weeks of age compared to single Tg(MMTV-PyVT)634Mul transgenic mice

♀ • tumors do not show malignant features and appear more like benign adenomas

♀ • the number of proliferating cells is much lower in tumors

♀ • marker analysis indicates a basal-to-luminal cell fate change in mammary tumor cells

♀ • reduction in the percentage of the CD24+CD90+ cancer stem cell population in mammary tumors compared to Tg(MMTV-PyVT)634Mul tumors

♀ • limiting-dilution transplantation assays indicate that tumor cells show an approximate 13-fold decrease in tumor-initiating ability

integument

decreased mammary gland tumor incidence ( J:271420 )

♀ • development of primary mammary lesions is suppressed at 12 and 16 weeks of age compared to single Tg(MMTV-PyVT)634Mul transgenic mice

♀ • tumors do not show malignant features and appear more like benign adenomas

♀ • the number of proliferating cells is much lower in tumors

♀ • marker analysis indicates a basal-to-luminal cell fate change in mammary tumor cells

♀ • reduction in the percentage of the CD24+CD90+ cancer stem cell population in mammary tumors compared to Tg(MMTV-PyVT)634Mul tumors

♀ • limiting-dilution transplantation assays indicate that tumor cells show an approximate 13-fold decrease in tumor-initiating ability

Genotype
MGI:5825262

cx63

• Allelic Composition: Ddr2^{tm1a(EUCOMM)Wtsi}/Ddr2^{tm1a(EUCOMM)Wtsi}; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6N * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:236031 )

• mice develop primary mammary gland tumors with a similar latency and burden as single Tg(MMTV-PyVT)634Mul/0 mice

decreased metastatic potential ( J:236031 )

• mice show a reduction in the number of macroscopic and microscopic metastases in the lungs compared to single Tg(MMTV-PyVT)634Mul/0 mice

integument

increased mammary gland tumor incidence ( J:236031 )

• mice develop primary mammary gland tumors with a similar latency and burden as single Tg(MMTV-PyVT)634Mul/0 mice

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:236031 )

• mice develop primary mammary gland tumors with a similar latency and burden as single Tg(MMTV-PyVT)634Mul/0 mice

Genotype
MGI:5825263

cx64

• Allelic Composition: Ddr2^{tm1b(EUCOMM)Wtsi}/Ddr2^{tm1b(EUCOMM)Wtsi}; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6N * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:236031 )

• mice develop primary mammary gland tumors with a similar latency and burden as single Tg(MMTV-PyVT)634Mul/0 mice

decreased metastatic potential ( J:236031 )

• mice show a reduction in the number of macroscopic and microscopic metastases in the lungs compared to single Tg(MMTV-PyVT)634Mul/0 mice

integument

increased mammary gland tumor incidence ( J:236031 )

• mice develop primary mammary gland tumors with a similar latency and burden as single Tg(MMTV-PyVT)634Mul/0 mice

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:236031 )

• mice develop primary mammary gland tumors with a similar latency and burden as single Tg(MMTV-PyVT)634Mul/0 mice

Genotype
MGI:7354957

cx65

• Allelic Composition: Trim11^em1Bcgen/Trim11⁺; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6N * FVB/N

neoplasm

decreased tumor growth/size ( J:329445 )

• breast tumors grow much slower than in hemizygous Tg(MMTV-PyVT)634Mul mice, with smaller tumor weight and volume

Genotype
MGI:6460271

cx66

• Allelic Composition: Ccdc25^em1Smoc/Ccdc25^em1Smoc; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6NTac * FVB/N

neoplasm

decreased metastatic potential ( J:291299 )

• induced by nasal instillation of LPS in the lungs

• in the liver of mice injected with breast tumor cells

• however, primary tumor growth is normal

Genotype
MGI:5431552

cx67

• Allelic Composition: Anxa1^tm1Rjf/Anxa1^tm1Rjf; Tg(MMTV-PyVT)634Mul/?
• Genetic Background: involves: FVB/N

neoplasm

decreased metastatic potential ( J:174635 )

• metastasis to lungs is reduced

decreased tumor growth/size ( J:174635 )

• although tumor susceptibility is normal, tumor growth is reduced

Genotype
MGI:3579341

cx68

• Allelic Composition: Mtes1^NZB/BlNJ/Mtes1^NZB/BlNJ; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: FVB/NJ * FVB/N-Tg(MMTV-PyVT)634Mul/J * I/LnJ

neoplasm

decreased tumor growth/size ( J:97671 )

• reduced mammary tumor mass

• decreased size and number of metastatic pulmonary tumors

Genotype
MGI:3579340

cx69

• Allelic Composition: Mmtp3^NZB/BlNJ/Mmtp3^NZB/BlNJ; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: FVB/NJ * FVB/N-Tg(MMTV-PyVT)634Mul/J * I/LnJ

neoplasm

decreased tumor growth/size ( J:97671 )

• reduced mammary tumor mass

• decreased size and number of metastatic pulmonary tumors

Genotype
MGI:3579339

cx70

• Allelic Composition: Mmtp2^NZB/BlNJ/Mmtp2^NZB/BlNJ; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: FVB/NJ * FVB/N-Tg(MMTV-PyVT)634Mul/J * I/LnJ

neoplasm

decreased tumor growth/size ( J:97671 )

• decreased size and number of pulmonary metastatic tumors

• decreased mammary tumor mass

Genotype
MGI:3579338

cx71

• Allelic Composition: Mmtp1^I/LnJ/Mmtp1^I/LnJ; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: FVB/NJ * FVB/N-Tg(MMTV-PyVT)634Mul/J * I/LnJ

neoplasm

decreased tumor growth/size ( J:97671 )

• decreased mammary tumor mass

abnormal tumor susceptibility ( J:97671 )

• increased mammary tumor progression

Genotype
MGI:5807361

cx72

• Allelic Composition: Slc6a14^tm1Gana/Slc6a14^tm1Gana; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: Not Specified

neoplasm

decreased metastatic potential ( J:226105 )

♀ • at 4 months of age, no metastatic nodules are detected in the lung, unlike in mice carrying the transgene on a wild-type background

decreased tumor growth/size ( J:226105 )

♀ • at 4 months of age, total mammary tumor volume is significantly lower than that in mice carrying the transgene on a wild-type background which exhibit tumor sizes of 2000-2500 mm³

♀ • decreased mammary tumor growth is associated with amino acid deficiency and a marked decrease in cell proliferation, mTOR phosphorylation, and HIF1alpha signaling

increased tumor latency ( J:226105 )

♀ • no mice develop mammary tumors at 3 months of age, whereas all mice carrying the transgene on a wild-type background start developing tumors in multiple mammary glands at ~72 days

♀ • small tumor nodules are, however, detectable at 4 months of age, indicating a significant delay in mammary tumor development

homeostasis/metabolism

abnormal amino acid level ( J:226105 )

♀ • mammary tumors exhibit amino acid starvation, as evidenced by the increased mRNA levels for asparagine synthetase (ASNS) and CHOP (CCAAT/enhancer-binding protein homologous protein), two genes that are responsive to changes in the amino acid nutritional status of cells

♀ • however, tumor tissues show no compensatory changes in mRNA expression of other amino acid transporters

immune system

abnormal immunoglobulin level ( J:226105 )

♀ • surprisingly, mammary tumors exhibit a marked upregulation of immunoglobulin genes, suggesting a boost in tumor immunity

hematopoietic system

abnormal immunoglobulin level ( J:226105 )

♀ • surprisingly, mammary tumors exhibit a marked upregulation of immunoglobulin genes, suggesting a boost in tumor immunity

Genotype
MGI:7834440

tg73

• Allelic Composition: Tg(MMTV-PyVT)634Mul/0
• Genetic Background: B6.FVB-Tg(MMTV-PyVT)634Mul

neoplasm

increased mammary gland tumor incidence ( J:350496 )

• tumors show glandular differentiation and moderated proliferation and tumors show loss of estrogen receptor and progesterone receptor expression and increased HER2 expression following tumor progression

• mice show extensive hyperplasia and multiple tumor foci as early as 4 weeks

increased mammary adenocarcinoma incidence ( J:350496 )

• in late stage of carcinoma, estrogen receptor (ER)-negative cells account for >90% of the tumor volume with scattered clusters of ER+ cells in a small area in 80% of mice while in the other 20% of mice, the amount of ER+ cells in tumors is about 40-50%, suggesting that these tumor cells have not progressed the malignant stage

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:350496 )

• tumors show glandular differentiation and moderated proliferation and tumors show loss of estrogen receptor and progesterone receptor expression and increased HER2 expression following tumor progression

• mice show extensive hyperplasia and multiple tumor foci as early as 4 weeks

increased mammary adenocarcinoma incidence ( J:350496 )

• in late stage of carcinoma, estrogen receptor (ER)-negative cells account for >90% of the tumor volume with scattered clusters of ER+ cells in a small area in 80% of mice while in the other 20% of mice, the amount of ER+ cells in tumors is about 40-50%, suggesting that these tumor cells have not progressed the malignant stage

integument

increased mammary gland tumor incidence ( J:350496 )

• tumors show glandular differentiation and moderated proliferation and tumors show loss of estrogen receptor and progesterone receptor expression and increased HER2 expression following tumor progression

• mice show extensive hyperplasia and multiple tumor foci as early as 4 weeks

increased mammary adenocarcinoma incidence ( J:350496 )

• in late stage of carcinoma, estrogen receptor (ER)-negative cells account for >90% of the tumor volume with scattered clusters of ER+ cells in a small area in 80% of mice while in the other 20% of mice, the amount of ER+ cells in tumors is about 40-50%, suggesting that these tumor cells have not progressed the malignant stage

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:350496

Genotype
MGI:3841379

tg74

• Allelic Composition: Tg(MMTV-PyVT)634Mul/0
• Genetic Background: FVB/N-Tg(MMTV-PyVT)634Mul/J

neoplasm

increased mammary gland tumor incidence ( J:140033 , J:147458 )

• mice develop mammary gland tumors with a median age of tumor latency of 66 days in females and 133.5 days in males unlike wild-type mice (J:147458)

abnormal tumor morphology ( J:140033 )

• metastatic lung tumors exhibit more blood vessel staining compared with equivalent tumors in Mmp9^tm1Tvu/Mmp9^tm1Tvu Tg(MMTV-PyVT)634Mul mice

increased tumor growth/size ( J:140033 )

• proliferation and apoptosis of tumor cells are increased compared with cells from Mmp9^tm1Tvu/Mmp9^tm1Tvu Tg(MMTV-PyVT)634Mul mice with the balance resulting in increased tumor size

respiratory system

increased lung weight ( J:147458 )

integument

increased mammary gland tumor incidence ( J:140033 , J:147458 )

• mice develop mammary gland tumors with a median age of tumor latency of 66 days in females and 133.5 days in males unlike wild-type mice (J:147458)

growth/size/body

increased lung weight ( J:147458 )

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:140033 , J:147458 )

• mice develop mammary gland tumors with a median age of tumor latency of 66 days in females and 133.5 days in males unlike wild-type mice (J:147458)

Genotype
MGI:2679598

tg75

• Allelic Composition: Tg(MMTV-PyVT)634Mul/0
• Genetic Background: FVB/N-Tg(MMTV-PyVT)634Mul/Nci

neoplasm

increased mammary adenocarcinoma incidence ( J:46460 , J:48285 , J:51424 , J:87544 )

• all female carriers develop palpable mammary tumors by 5 weeks of age; male carriers also develop these tumors with a later age of onset (median 83 days of age) (J:46460)

• tumors are multifocal, highly fibrotic, and involved the entire mammary fat pad (J:46460)

• mammary tumors appear in males and females with 100% penetrance by 40 days of age (J:51424)

increased metastatic potential ( J:46460 , J:48285 )

• pulmonary metastases are observed in 94% of tumor-bearing female mice and 80% of tumor-bearing male mice (J:46460)

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:46460 , J:48285 , J:51424 , J:87544 )

• all female carriers develop palpable mammary tumors by 5 weeks of age; male carriers also develop these tumors with a later age of onset (median 83 days of age) (J:46460)

• tumors are multifocal, highly fibrotic, and involved the entire mammary fat pad (J:46460)

• mammary tumors appear in males and females with 100% penetrance by 40 days of age (J:51424)

lactation failure ( J:46460 )

♀ • inability to lactate from the time of the first pregnancy

integument

increased mammary adenocarcinoma incidence ( J:46460 , J:48285 , J:51424 , J:87544 )

• all female carriers develop palpable mammary tumors by 5 weeks of age; male carriers also develop these tumors with a later age of onset (median 83 days of age) (J:46460)

• tumors are multifocal, highly fibrotic, and involved the entire mammary fat pad (J:46460)

• mammary tumors appear in males and females with 100% penetrance by 40 days of age (J:51424)

lactation failure ( J:46460 )

♀ • inability to lactate from the time of the first pregnancy

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:46460

Genotype
MGI:3804002

tg76

• Allelic Composition: Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129 * C57BL/6 * FVB/N

neoplasm

increased mammary adenocarcinoma incidence ( J:117336 )

• all female virgin mice develop cancer tumors in the breast by 14 weeks of age

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:117336 )

• all female virgin mice develop cancer tumors in the breast by 14 weeks of age

integument

increased mammary adenocarcinoma incidence ( J:117336 )

• all female virgin mice develop cancer tumors in the breast by 14 weeks of age

Genotype
MGI:3841381

tg77

• Allelic Composition: Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: C57BL/6 * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:147458 )

• mice develop mammary gland tumors with a median age of tumor latency of 73 days in females and 137 days in males unlike wild-type mice

respiratory system

increased lung weight ( J:147458 )

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:147458 )

• mice develop mammary gland tumors with a median age of tumor latency of 73 days in females and 137 days in males unlike wild-type mice

growth/size/body

increased lung weight ( J:147458 )

integument

increased mammary gland tumor incidence ( J:147458 )

• mice develop mammary gland tumors with a median age of tumor latency of 73 days in females and 137 days in males unlike wild-type mice

Genotype
MGI:4361924

tg78

• Allelic Composition: Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: FVB/N

neoplasm

increased mammary gland tumor incidence ( J:133325 , J:236031 )

• average onset of tumor development is 66 days (J:133325)

• tumor nodules are present throughout the entire mammary gland (J:133325)

• extensive adenomas are found (J:133325)

• primary tumors are highly fibrotic (J:236031)

• tumors exhibit more linear, thicker collagen fibers consistent with aggressive and invasive tumors (J:236031)

• tumors have higher CD31 staining, indicating increased primary tumor vasculature (J:236031)

endocrine/exocrine glands

abnormal mammary gland morphology ( J:133325 )

♀ • tumor nodules are present throughout the entire mammary gland

increased mammary gland tumor incidence ( J:133325 , J:236031 )

• average onset of tumor development is 66 days (J:133325)

• tumor nodules are present throughout the entire mammary gland (J:133325)

• extensive adenomas are found (J:133325)

• primary tumors are highly fibrotic (J:236031)

• tumors exhibit more linear, thicker collagen fibers consistent with aggressive and invasive tumors (J:236031)

• tumors have higher CD31 staining, indicating increased primary tumor vasculature (J:236031)

integument

abnormal mammary gland morphology ( J:133325 )

♀ • tumor nodules are present throughout the entire mammary gland

increased mammary gland tumor incidence ( J:133325 , J:236031 )

• average onset of tumor development is 66 days (J:133325)

• tumor nodules are present throughout the entire mammary gland (J:133325)

• extensive adenomas are found (J:133325)

• primary tumors are highly fibrotic (J:236031)

• tumors exhibit more linear, thicker collagen fibers consistent with aggressive and invasive tumors (J:236031)

• tumors have higher CD31 staining, indicating increased primary tumor vasculature (J:236031)

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:236031

Genotype
MGI:3032640

tg79

• Allelic Composition: Tg(MMTV-PyVT)634Mul/0
• Genetic Background: multiple strains

neoplasm

decreased mammary gland tumor incidence ( J:48854 )

• in F1 FVB/N mice crossed to the P/J, DBA/1J, NZW/LacJ, C57BL/6NIcr, CAST/Ei, NOD/LtJ, CBA/CaJ, SWR/J, AKR/J, BUB/BnJ, ST/J, KK/HiJ, or MOLF/Ei strains, an increased latency of the onset of the appearance of primary mammary tumors is seen compared to the inbred FVB/N strain

increased mammary adenocarcinoma incidence ( J:48854 )

• in F1 FVB/N mice crossed to either the I/LnJ or C58/J strains, an acceleration of the onset of the appearance of primary mammary tumors is seen compared to the inbred FVB/N strain

decreased metastatic potential ( J:48854 )

• in F1 FVB/N mice crossed to the RF/J, C58/J, C57BR/cdJ, NZB/B1NJ, I/LnJ, DBA/2J, KK/HiJ, MOLF/Ei, SEA/GnJ, NZW/LacJ, or CE/J strains, an decrease in pulmonary metastatic index is seen

increased metastatic potential ( J:48854 )

• in F1 FVB/N mice crossed to the AKR/J strain, an increase in pulmonary metastatic index is seen

integument

decreased mammary gland tumor incidence ( J:48854 )

• in F1 FVB/N mice crossed to the P/J, DBA/1J, NZW/LacJ, C57BL/6NIcr, CAST/Ei, NOD/LtJ, CBA/CaJ, SWR/J, AKR/J, BUB/BnJ, ST/J, KK/HiJ, or MOLF/Ei strains, an increased latency of the onset of the appearance of primary mammary tumors is seen compared to the inbred FVB/N strain

increased mammary adenocarcinoma incidence ( J:48854 )

• in F1 FVB/N mice crossed to either the I/LnJ or C58/J strains, an acceleration of the onset of the appearance of primary mammary tumors is seen compared to the inbred FVB/N strain

endocrine/exocrine glands

decreased mammary gland tumor incidence ( J:48854 )

• in F1 FVB/N mice crossed to the P/J, DBA/1J, NZW/LacJ, C57BL/6NIcr, CAST/Ei, NOD/LtJ, CBA/CaJ, SWR/J, AKR/J, BUB/BnJ, ST/J, KK/HiJ, or MOLF/Ei strains, an increased latency of the onset of the appearance of primary mammary tumors is seen compared to the inbred FVB/N strain

increased mammary adenocarcinoma incidence ( J:48854 )

• in F1 FVB/N mice crossed to either the I/LnJ or C58/J strains, an acceleration of the onset of the appearance of primary mammary tumors is seen compared to the inbred FVB/N strain